TIGIT

Note

TIGIT 타겟 임상시험 모니터링

Visual Summary

Change History

NCT05607563

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `identificationModule.organization.fullName` changed from `Biotheus Inc.` to `BioNTech SE`

NCT05394168

  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT04995523

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-20` to `2026-07-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-24` to `2026-07-14`
    • New field added: `root['contactsLocationsModule']['locations'][34]['zip']`
  • 2026-03-25 02:23:20 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-08-18` to `2026-08-28`
    • Field `statusModule.completionDateStruct.date` changed from `2028-03-16` to `2028-06-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-21` to `2026-03-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-24` to `2026-03-24`
    • Field `designModule.enrollmentInfo.count` changed from `210` to `212`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}` to `{'facility': 'Research Site', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}`
    • Field `contactsLocationsModule.locations.[20]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Tbilisi', 'zip': '0112', 'country': 'Georgia', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}` to `{'facility': 'Research Site', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}` to `{'facility': 'Research Site', 'city': 'Melbourne', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}`
    • Field `contactsLocationsModule.locations.[11]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Porto Alegre', 'zip': '90035903', 'country': 'Brazil', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}` to `{'facility': 'Research Site', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}` to `{'facility': 'Research Site', 'city': 'Anderlecht', 'zip': '1070', 'country': 'Belgium', 'geoPoint': {'lat': 50.83619, 'lon': 4.31454}}`
    • Field `contactsLocationsModule.locations.[19]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}` to `{'facility': 'Research Site', 'city': 'Sendai', 'zip': '981-0914', 'country': 'Japan', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}`
    • Field `contactsLocationsModule.locations.[13]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'São Paulo', 'zip': '01246-000', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}` to `{'facility': 'Research Site', 'city': 'Copenhagen', 'zip': '2100', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21201', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}` to `{'facility': 'Research Site', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}`
    • Field `contactsLocationsModule.locations.[6]` changed from `{'facility': 'Research Site', 'status': 'COMPLETED', 'city': 'Melbourne', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}` to `{'facility': 'Research Site', 'city': 'Florianópolis', 'zip': '88034-000', 'country': 'Brazil', 'geoPoint': {'lat': -27.59667, 'lon': -48.54917}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}` to `{'facility': 'Research Site', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}`
    • Field `contactsLocationsModule.locations.[39]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}` to `{'facility': 'Research Site', 'city': 'Muang', 'zip': '50200', 'country': 'Thailand'}`
    • Field `contactsLocationsModule.locations.[18]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Dijon', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}` to `{'facility': 'Research Site', 'city': 'Niigata', 'zip': '951-8566', 'country': 'Japan', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Rio de Janeiro', 'zip': '20231-050', 'country': 'Brazil', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}` to `{'facility': 'Research Site', 'city': 'Chongqing', 'zip': '400030', 'country': 'China', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Natal', 'zip': '59075-740', 'country': 'Brazil', 'geoPoint': {'lat': -5.795, 'lon': -35.20944}}` to `{'facility': 'Research Site', 'city': 'São Paulo', 'zip': '01246-000', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}`
    • Field `contactsLocationsModule.locations.[25]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kuala Lumpur', 'zip': '59100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}` to `{'facility': 'Research Site', 'city': 'Leiden', 'zip': '2333 ZA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}`
    • Field `contactsLocationsModule.locations.[27]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chisinau', 'zip': 'MD-2025', 'country': 'Moldova', 'geoPoint': {'lat': 47.00902, 'lon': 28.85938}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '03082', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Florianópolis', 'zip': '88034-000', 'country': 'Brazil', 'geoPoint': {'lat': -27.59667, 'lon': -48.54917}}` to `{'facility': 'Research Site', 'city': 'Rio de Janeiro', 'zip': '20231-050', 'country': 'Brazil', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}`
    • Field `contactsLocationsModule.locations.[32]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '03082', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Madrid', 'zip': '28041', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Anderlecht', 'zip': '1070', 'country': 'Belgium', 'geoPoint': {'lat': 50.83619, 'lon': 4.31454}}` to `{'facility': 'Research Site', 'city': 'Natal', 'zip': '59075-740', 'country': 'Brazil', 'geoPoint': {'lat': -5.795, 'lon': -35.20944}}`
    • Field `contactsLocationsModule.locations.[17]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Copenhagen', 'zip': '2100', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}` to `{'facility': 'Research Site', 'city': 'Kashiwa', 'zip': '227-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}` to `{'facility': 'Research Site', 'city': 'Porto Alegre', 'zip': '90035903', 'country': 'Brazil', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}` to `{'facility': 'Research Site', 'city': 'Dijon', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}`
    • Field `contactsLocationsModule.locations.[28]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Groningen', 'zip': '9713 GZ', 'country': 'Netherlands', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '03722', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Chongqing', 'zip': '400030', 'country': 'China', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}` to `{'facility': 'Research Site', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}`
    • Field `contactsLocationsModule.locations.[26]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kuching', 'zip': '93586', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}` to `{'facility': 'Research Site', 'city': 'Utrecht', 'zip': '3584 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}`
    • Field `contactsLocationsModule.locations.[24]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}` to `{'facility': 'Research Site', 'city': 'Groningen', 'zip': '9713 GZ', 'country': 'Netherlands', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}`
    • Field `contactsLocationsModule.locations.[29]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Leiden', 'zip': '2333 ZA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[23]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Sendai', 'zip': '981-0914', 'country': 'Japan', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}` to `{'facility': 'Research Site', 'city': 'Chisinau', 'zip': 'MD-2025', 'country': 'Moldova', 'geoPoint': {'lat': 47.00902, 'lon': 28.85938}}`
    • Field `contactsLocationsModule.locations.[21]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kashiwa', 'zip': '227-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}` to `{'facility': 'Research Site', 'city': 'Kuala Lumpur', 'zip': '59100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}`
    • Field `contactsLocationsModule.locations.[33]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '03722', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Taichung', 'zip': '40201', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}`
    • Field `contactsLocationsModule.locations.[0]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Orange', 'state': 'California', 'zip': '92868', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}` to `{'facility': 'Research Site', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}`
    • Field `contactsLocationsModule.locations.[35]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}` to `{'facility': 'Research Site', 'city': 'Tainan', 'zip': '70403', 'country': 'Taiwan', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}`
    • Field `contactsLocationsModule.locations.[22]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Niigata', 'zip': '951-8566', 'country': 'Japan', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}` to `{'facility': 'Research Site', 'city': 'Kuching', 'zip': '93586', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}`
    • Field `contactsLocationsModule.locations.[36]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}` to `{'facility': 'Research Site', 'city': 'Taipei', 'zip': '110', 'country': 'Taiwan', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}`
    • Field `contactsLocationsModule.locations.[38]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Taichung', 'zip': '40201', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}` to `{'facility': 'Research Site', 'city': 'Chanthaburi', 'zip': '22000', 'country': 'Thailand', 'geoPoint': {'lat': 12.60961, 'lon': 102.10447}}`
    • Field `contactsLocationsModule.locations.[34]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}`
    • Field `contactsLocationsModule.locations.[16]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Wuhan', 'zip': '430022', 'country': 'China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}` to `{'facility': 'Research Site', 'city': 'Tbilisi', 'zip': '0112', 'country': 'Georgia', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}`
    • Field `contactsLocationsModule.locations.[30]` changed from `{'facility': 'Research Site', 'status': 'COMPLETED', 'city': 'Utrecht', 'zip': '3584 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}` to `{'facility': 'Research Site', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}`
    • Field `contactsLocationsModule.locations.[37]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Madrid', 'zip': '28041', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}` to `{'facility': 'Research Site', 'city': 'Bangkok', 'zip': '10700', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}`
    • Field `contactsLocationsModule.locations.[31]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Singapore', 'zip': '308433', 'country': 'Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}` to `{'facility': 'Research Site', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`

NCT05130177

  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-05` to `2026-03`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2028-01` to `2026-02-06`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2031-01` to `2030-01-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-05-02` to `2026-03-25`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-07` to `2026-03-31`
    • Field `designModule.enrollmentInfo.count` changed from `26` to `8`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
    • Field removed: `root['oversightModule']['isUsExport']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT04047862

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[64]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[64]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[64]geoPoint.lon` changed from `121.3187` to `121.29696`

NCT05537051

  • 2026-07-28 00:26:04 (Trial Update)
    • Field `identificationModule.organization.fullName` changed from `Biotheus Inc.` to `BioNTech SE`

NCT05061628

  • 2026-07-28 00:26:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2021-08` to `2026-07`
    • Field `statusModule.overallStatus` changed from `UNKNOWN` to `COMPLETED`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2023-08-14` to `2023-04-23`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2024-09-30` to `2023-04-23`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2021-09-21` to `2026-07-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2021-09-29` to `2026-07-09`
    • Field `designModule.designInfo.allocation` changed from `NA` to `NON_RANDOMIZED`
    • Field `designModule.designInfo.maskingInfo.masking` changed from `NONE` to `SINGLE`
    • Field `designModule.enrollmentInfo.count` changed from `176` to `47`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['designModule']['designInfo']['maskingInfo']['whoMasked']`
    • Field removed: `root['statusModule']['lastKnownStatus']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT04656535

  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-30` to `2026-03-17`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-06` to `2026-04-15`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-07` to `2026-04-17`

NCT05060432

  • 2026-07-28 00:26:04 (Trial Update)
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT06713798

  • 2026-03-24 02:11:00 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-06` to `2026-03`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `statusModule.startDateStruct.date` changed from `2025-07` to `2025-01-30`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2028-01` to `2025-09-15`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2030-01` to `2025-09-15`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-06-23` to `2026-03-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-06-24` to `2026-03-23`
    • Field `designModule.enrollmentInfo.count` changed from `115` to `0`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`
    • Field removed: `root['contactsLocationsModule']`

NCT05394337

  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-10` to `2026-04`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2025-12-31` to `2028-12-31`
    • Field `statusModule.completionDateStruct.date` changed from `2025-12-31` to `2028-12-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-07` to `2026-04-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-09` to `2026-05-05`
    • Field removed: `root['ipdSharingStatementModule']`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
    • Field removed: `root['oversightModule']['isUsExport']`

NCT05294952

  • 2026-03-03 00:59:11 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT06754501

  • 2026-02-19 01:00:00 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-02`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-01` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-07` to `2026-02-18`
    • Field `designModule.enrollmentInfo.count` changed from `35` to `4`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT05805501

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-10` to `2026-05-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-12` to `2026-05-12`
  • 2026-02-16 21:08:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-31` to `2026-10-31`
    • Field `statusModule.completionDateStruct.date` changed from `2026-07-31` to `2026-10-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-12` to `2026-02-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-13` to `2026-02-12`

NCT04672369

  • 2026-06-06 03:35:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[0]city` changed from `Jilin` to `Jilin City`

NCT04672356

  • 2026-06-06 03:35:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[0]city` changed from `Jilin` to `Jilin City`

NCT05009069

  • 2026-07-29 02:40:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-16` to `2026-07-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-21` to `2026-07-28`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.completionDateStruct.date` changed from `2026-11-06` to `2026-11-10`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-16` to `2026-04-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-22` to `2026-04-21`
  • 2026-02-28 00:50:46 (Trial Update)
    • New field added: `root['referencesModule']`

NCT04354246

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-05` to `2026-05`
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `COMPLETED`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2025-12-30` to `2026-04-01`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2025-12-30` to `2026-04-01`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-05-18` to `2026-05-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-22` to `2026-05-12`
    • Field `designModule.enrollmentInfo.count` changed from `110` to `94`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`

NCT05414032

  • 2026-02-26 00:55:49 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-03` to `2026-02`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07` to `2027-09`
    • Field `statusModule.completionDateStruct.date` changed from `2026-07` to `2028-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-03-25` to `2026-02-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-03-30` to `2026-02-25`
    • Field `descriptionModule.briefSummary` changed from `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 200 patients are expected to be enrolled.` to `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.`
    • Field `descriptionModule.detailedDescription` changed from `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 200 patients are expected to be enrolled.
    • The study is divided in 5 parts:
    • Part A and Part B are common for all patients in the study, which are defined as the periods of definitive treatment and post definitive treatment. Definitive treatment will be either surgery followed by radiation or chemoradiation; definitive radiation or definitive chemoradiation according to standard of care (SOC) in our institution. A baseline ctDNA sample collection and CT staging will be done before treatment. ctDNA analysis will be performed in Part B at approximately week 5 and at week 10 of this period, and patients will be classified as MRD positive or MRD negative based on the week 10 results. If a patient has equivocal results, a new sample will be taken around week 14. Patients who receive surgery as part of their treatment, will also get ctDNA analysis post-surgery.
    • Part C is the randomized and interventional part of the study (n=60) for patients with MRD. The patient will be randomized 3:1 to Arm A (treatment with AZD2936) or Arm B (observation). Patients in Arm A will continue treatment until the occurrence of any of these circumstances: after completion of 6 cycles, intolerable toxicity or patient decision. ctDNA analysis will be done at week 10 of Part C.
    • Part D is the follow up part for patients with MRD. Two ctDNA samples will be analyzed at week 2 and at week 10 of Part D. Plasma samples will be collected every 6 months for the first 3 years and a final sample will be also collected if the patient has radiological or clinical progression. A CT/MRI scan will be performed at week 2 of Part D and, if clinically needed, according to SOC.
    • Part E is the observational follow up part for patients without MRD. A ctDNA sample will be collected at the time of the first follow up and at radiological or clinical progression if applicable.` to `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.
    • The study is divided in 5 parts:
    • Part A and Part B are common for all patients in the study, which are defined as the periods of definitive treatment and post definitive treatment. Definitive treatment will be either surgery followed by radiation or chemoradiation; definitive radiation or definitive chemoradiation according to standard of care (SOC) in our institution. A baseline ctDNA sample collection and CT staging will be done before treatment. ctDNA analysis will be performed in Part B at approximately week 5, week 10, week 26 and week 52 of this period, and patients will be classified as MRD positive or MRD negative. Patients who receive surgery as part of their treatment, will also get ctDNA analysis post-surgery.
    • Part C is the interventional part of the study (n=14) for patients with MRD or radiological/clinical progression. Patients will continue treatment until the occurrence of any of these circumstances: after completion of 6 cycles, intolerable toxicity or patient decision. ctDNA analysis will be done at week 10 of Part C.
    • Part D is the follow up part for patients with MRD or radiological/clinical progression. Two ctDNA samples will be analyzed at week 2 and at week 10 of Part D. Plasma samples will be collected every 6 months for the first 3 years and a final sample will be also collected if the patient has radiological or clinical progression. A CT/MRI scan will be performed at week 2 of Part D and, if clinically needed, according to SOC.
    • Part E is the observational follow up part for patients without MRD at the completion of part B or with MRD but fail screening to enter Parts C and D. ctDNA samples will be collected at radiological or clinical progression. Additional plasma samples at 6 and 12 months after completion of part B are strongly recommended.`
    • Field `designModule.enrollmentInfo.count` changed from `200` to `102`
    • Field `armsInterventionsModule.armGroups.[0]label` changed from `MRD positive Cohort - Arm A (treatment)` to `MRD positive and/or radiological/clinical progression Cohort`
    • Field `armsInterventionsModule.interventions.[0]armGroupLabels.[0]` changed from `MRD positive Cohort - Arm A (treatment)` to `MRD positive and/or radiological/clinical progression Cohort`

NCT05568095

  • 2026-07-28 00:26:04 (Trial Update)
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-06` to `2026-08`
    • Field `statusModule.completionDateStruct.date` changed from `2026-06` to `2026-08`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-29` to `2026-07-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-02` to `2026-07-21`
  • 2026-06-24 14:19:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[115]geoPoint.lat` changed from `14.90871` to `28.82333`
    • Field `contactsLocationsModule.locations.[115]geoPoint.lon` changed from `-92.26131` to `-111.94062`
    • Field `contactsLocationsModule.locations.[118]geoPoint.lat` changed from `25.6604` to `25.66158`
    • Field `contactsLocationsModule.locations.[118]geoPoint.lon` changed from `-100.40651` to `-100.4034`
  • 2026-06-03 04:13:53 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-06` to `2026-05-29`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-08` to `2026-06-02`
  • 2026-05-30 03:31:20 (Trial Update)
    • Field `contactsLocationsModule.locations.[117]geoPoint.lat` changed from `29.02751` to `14.90871`
    • Field `contactsLocationsModule.locations.[117]geoPoint.lon` changed from `-100.90108` to `-92.26131`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-04` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-31` to `2026-05-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-02` to `2026-05-08`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': 'SCRI - Florida Cancer Specialists - North Region Research Office', 'city': 'St. Petersburg', 'state': 'Florida', 'zip': '33705', 'country': 'United States', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}` to `{'facility': 'Research Site', 'city': 'St. Petersburg', 'state': 'Florida', 'zip': '33705', 'country': 'United States', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}`
    • Field `contactsLocationsModule.locations.[158]` changed from `{'facility': 'Szpital Miejski w Tychach', 'city': 'Tychy', 'country': 'Poland', 'geoPoint': {'lat': 50.13717, 'lon': 18.96641}}` to `{'facility': 'Research Site', 'city': 'Edirne', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 41.67719, 'lon': 26.55597}}`
    • Field `contactsLocationsModule.locations.[150]` changed from `{'facility': 'Hospital Maria Auxiliadora', 'city': 'San Juán de Miraflores', 'country': 'Peru', 'geoPoint': {'lat': -11.93531, 'lon': -75.41647}}` to `{'facility': 'Research Site', 'city': 'Santander', 'country': 'Spain', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}`
    • Field `contactsLocationsModule.locations.[55]` changed from `{'facility': 'Sunnybrook Health Sciences Centre - Bayview Campus', 'city': 'Toronto', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}` to `{'facility': 'Research Site', 'city': 'Guangzhou', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}`
    • Field `contactsLocationsModule.locations.[102]` changed from `{'facility': 'Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet', 'city': 'Budapest', 'country': 'Hungary', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}` to `{'facility': 'Research Site', 'city': 'Nagaizumi-cho', 'country': 'Japan'}`
    • Field `contactsLocationsModule.locations.[111]` changed from `{'facility': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele', 'city': 'Milan', 'country': 'Italy', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}` to `{'facility': 'Research Site', 'city': 'Kaunas', 'country': 'Lithuania', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}`
    • Field `contactsLocationsModule.locations.[40]` changed from `{'facility': 'CORI', 'city': 'La Rioja', 'country': 'Argentina', 'geoPoint': {'lat': -29.41328, 'lon': -66.85637}}` to `{'facility': 'Research Site', 'city': 'Natal', 'country': 'Brazil', 'geoPoint': {'lat': -5.795, 'lon': -35.20944}}`
    • Field `contactsLocationsModule.locations.[105]` changed from `{'facility': 'Pécsi Tudományegyetem Klinikai Központ', 'city': 'Pécs', 'country': 'Hungary', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}` to `{'facility': 'Research Site', 'city': 'Osaka', 'country': 'Japan', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}`
    • Field `contactsLocationsModule.locations.[34]` changed from `{'facility': 'The Center for Cancer & Blood Disorders - Fort Worth', 'city': 'Fort Worth', 'state': 'Texas', 'zip': '76104', 'country': 'United States', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}` to `{'facility': 'Research Site', 'city': 'La Rioja', 'country': 'Argentina', 'geoPoint': {'lat': -29.41328, 'lon': -66.85637}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'SCRI - Florida Cancer Specialists - East Region Research Office', 'city': 'West Palm Beach', 'state': 'Florida', 'zip': '33401', 'country': 'United States', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}` to `{'facility': 'Research Site', 'city': 'Louisville', 'state': 'Kentucky', 'zip': '40202', 'country': 'United States', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}`
    • Field `contactsLocationsModule.locations.[50]` changed from `{'facility': 'Instituto Nacional de Câncer - Brazil', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}` to `{'facility': 'Research Site', 'city': 'Santiago', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}`
    • Field `contactsLocationsModule.locations.[66]` changed from `{'facility': "Guangdong PR People's Hospital", 'city': 'Guangzhou', 'country': 'China', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}` to `{'facility': 'Research Site', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}`
    • Field `contactsLocationsModule.locations.[37]` changed from `{'facility': 'Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location', 'city': 'Seattle', 'state': 'Washington', 'zip': '98109', 'country': 'United States', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}` to `{'facility': 'Research Site', 'city': 'Murdoch', 'country': 'Australia', 'geoPoint': {'lat': -32.06987, 'lon': 115.83757}}`
    • Field `contactsLocationsModule.locations.[119]` changed from `{'facility': 'Chiba Cancer Center', 'city': 'Chiba', 'country': 'Japan', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}` to `{'facility': 'Research Site', 'city': 'Mérida', 'zip': '97134', 'country': 'Mexico', 'geoPoint': {'lat': 20.967, 'lon': -89.62318}}`
    • Field `contactsLocationsModule.locations.[162]` changed from `{'facility': 'Instituto Português de Oncologia do Porto Francisco Gentil', 'city': 'Porto', 'country': 'Portugal', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}` to `{'facility': 'Research Site', 'city': 'Mamak', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 41.48859, 'lon': 32.36864}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'Yale Cancer Center', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}` to `{'facility': 'Research Site', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}`
    • Field `contactsLocationsModule.locations.[106]` changed from `{'facility': 'Hadassah University Hospital Ein Kerem', 'city': 'Jerusalem', 'country': 'Israel', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}` to `{'facility': 'Research Site', 'city': 'Osakasayama-shi', 'country': 'Japan'}`
    • Field `contactsLocationsModule.locations.[108]` changed from `{'facility': 'Davidoff Cancer Center', 'city': 'Petah Tikva', 'country': 'Israel', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}` to `{'facility': 'Research Site', 'city': 'Saitama', 'country': 'Japan', 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}`
    • Field `contactsLocationsModule.locations.[161]` changed from `{'facility': 'Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud', 'city': 'Lisbon', 'country': 'Portugal', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}` to `{'facility': 'Research Site', 'city': 'Malatya', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 38.35018, 'lon': 38.31667}}`
    • Field `contactsLocationsModule.locations.[147]` changed from `{'facility': 'Centro Hemato - Oncológico Privado (CHOP)', 'city': 'Toluca', 'zip': '50120', 'country': 'Mexico', 'geoPoint': {'lat': 19.28786, 'lon': -99.65324}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[61]` changed from `{'facility': 'Pontificia Universidad Catolica de Chile - Escuela De Medicina - Clinica UC San Carlos de Apoq', 'city': 'Santiago', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}` to `{'facility': 'Research Site', 'city': 'Zhengzhou', 'country': 'China', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}`
    • Field `contactsLocationsModule.locations.[88]` changed from `{'facility': 'Evex Hospitals - Kutaisi Referral Hospital', 'city': 'Kutaisi', 'zip': '4600', 'country': 'Georgia', 'geoPoint': {'lat': 42.26791, 'lon': 42.69459}}` to `{'facility': 'Research Site', 'city': 'Florence', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'UCLA Health - Santa Monica Cancer Care', 'city': 'Santa Monica', 'state': 'California', 'zip': '90404', 'country': 'United States', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}` to `{'facility': 'Research Site', 'city': 'Santa Monica', 'state': 'California', 'zip': '90404', 'country': 'United States', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}`
    • Field `contactsLocationsModule.locations.[35]` changed from `{'facility': 'Harris Health System', 'city': 'Houston', 'state': 'Texas', 'zip': '77054', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}` to `{'facility': 'Research Site', 'city': 'Mar del Plata', 'country': 'Argentina', 'geoPoint': {'lat': -38.00042, 'lon': -57.5562}}`
    • Field `contactsLocationsModule.locations.[123]` changed from `{'facility': 'Cancer Inst Hosp of JFCR', 'city': 'Kōtō City', 'country': 'Japan', 'geoPoint': {'lat': 32.77856, 'lon': 130.74537}}` to `{'facility': 'Research Site', 'city': 'San Juán de Miraflores', 'country': 'Peru', 'geoPoint': {'lat': -11.93531, 'lon': -75.41647}}`
    • Field `contactsLocationsModule.locations.[39]` changed from `{'facility': 'Hospital Británico de Buenos Aires', 'city': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}` to `{'facility': 'Research Site', 'city': 'Ijuí', 'country': 'Brazil', 'geoPoint': {'lat': -28.38778, 'lon': -53.91472}}`
    • Field `contactsLocationsModule.locations.[82]` changed from `{'facility': 'Hôpital de la Timone', 'city': 'Marseille', 'country': 'France', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}` to `{'facility': 'Research Site', 'city': 'Budapest', 'country': 'Hungary', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}`
    • Field `contactsLocationsModule.locations.[13]` changed from `{'facility': 'Ochsner Cancer Institute', 'city': 'New Orleans', 'state': 'Louisian

NCT05327530

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-23` to `2026-04-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-26` to `2026-04-24`
    • Field `contactsLocationsModule.locations.[93]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[93]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[93]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-04-04 02:21:51 (Trial Update)
    • Field `contactsLocationsModule.locations.[63]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[63]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[63]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:09 (Trial Update)
    • Field `contactsLocationsModule.locations.[61]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lon` changed from `14.5195` to `14.26811`
    • Field `contactsLocationsModule.locations.[62]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[62]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[62]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT05520294

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT04465643

  • 2026-07-28 00:26:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-27` to `2026-07-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-29` to `2026-07-10`
  • 2026-05-30 03:31:20 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-10` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-02` to `2026-05-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-08` to `2026-05-29`
    • Field `outcomesModule.primaryOutcomes.[3]measure` changed from `Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who achieve a response` to `Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who start standard of care within standard treatment window`
    • Field `outcomesModule.primaryOutcomes.[3]description` changed from `Number of participants who achieve a response (improved progression free survival).` to `Number of participants who start standard of care treatment within 8 week`
    • Field `outcomesModule.primaryOutcomes.[3]timeFrame` changed from `Up to 2 years` to `Up to 8 weeks`

NCT04262856

  • 2026-06-16 04:16:42 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-09` to `2026-06-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-10` to `2026-06-15`
    • New field added: `root['statusModule']['dispFirstPostDateStruct']`
  • 2026-06-13 03:52:39 (Trial Update)
    • New field added: `root['statusModule']['dispFirstSubmitDate']`
  • 2026-06-11 04:04:07 (Trial Update)
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2025-06-05` to `2025-07-09`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-08-25` to `2026-06-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-26` to `2026-06-10`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[43]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lon` changed from `121.3187` to `121.29696`

NCT04736173

  • 2026-07-30 02:27:10 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-28` to `2026-07-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-01` to `2026-07-29`
    • Field `contactsLocationsModule.locations.[10]city` changed from `Davao City` to `Mexico City`
    • Field `contactsLocationsModule.locations.[10]country` changed from `Philippines` to `Mexico`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lat` changed from `7.07306` to `19.42847`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lon` changed from `125.61278` to `-99.12766`
    • Field `contactsLocationsModule.locations.[11]city` changed from `Manila` to `San Luis Potosí City`
    • Field `contactsLocationsModule.locations.[11]country` changed from `Philippines` to `Mexico`
    • Field `contactsLocationsModule.locations.[11]geoPoint.lat` changed from `14.6042` to `22.15234`
    • Field `contactsLocationsModule.locations.[11]geoPoint.lon` changed from `120.9822` to `-100.97135`
    • Field `contactsLocationsModule.locations.[12]city` changed from `George` to `Cebu`
    • Field `contactsLocationsModule.locations.[12]country` changed from `South Africa` to `Philippines`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lat` changed from `-33.963` to `16.75187`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lon` changed from `22.46173` to `121.5961`
    • Field `contactsLocationsModule.locations.[13]city` changed from `Johannesburg` to `Davao City`
    • Field `contactsLocationsModule.locations.[13]country` changed from `South Africa` to `Philippines`
    • Field `contactsLocationsModule.locations.[13]geoPoint.lat` changed from `-26.20227` to `7.07306`
    • Field `contactsLocationsModule.locations.[13]geoPoint.lon` changed from `28.04363` to `125.61278`
    • Field `contactsLocationsModule.locations.[14]city` changed from `Pretoria` to `Manila`
    • Field `contactsLocationsModule.locations.[14]country` changed from `South Africa` to `Philippines`
    • Field `contactsLocationsModule.locations.[14]geoPoint.lat` changed from `-25.74486` to `14.6042`
    • Field `contactsLocationsModule.locations.[14]geoPoint.lon` changed from `28.18783` to `120.9822`
    • Field `contactsLocationsModule.locations.[15]city` changed from `Daegu` to `Michalovce`
    • Field `contactsLocationsModule.locations.[15]country` changed from `South Korea` to `Slovakia`
    • Field `contactsLocationsModule.locations.[15]geoPoint.lat` changed from `35.87028` to `48.75434`
    • Field `contactsLocationsModule.locations.[15]geoPoint.lon` changed from `128.59111` to `21.9195`
    • Field `contactsLocationsModule.locations.[16]city` changed from `Incheon` to `George`
    • Field `contactsLocationsModule.locations.[16]country` changed from `South Korea` to `South Africa`
    • Field `contactsLocationsModule.locations.[16]geoPoint.lat` changed from `37.45646` to `-33.963`
    • Field `contactsLocationsModule.locations.[16]geoPoint.lon` changed from `126.70515` to `22.46173`
    • Field `contactsLocationsModule.locations.[17]city` changed from `Jinju` to `Johannesburg`
    • Field `contactsLocationsModule.locations.[17]country` changed from `South Korea` to `South Africa`
    • Field `contactsLocationsModule.locations.[17]geoPoint.lat` changed from `35.19278` to `-26.20227`
    • Field `contactsLocationsModule.locations.[17]geoPoint.lon` changed from `128.08472` to `28.04363`
    • Field `contactsLocationsModule.locations.[18]city` changed from `Seoul` to `Pretoria`
    • Field `contactsLocationsModule.locations.[18]country` changed from `South Korea` to `South Africa`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lat` changed from `37.566` to `-25.74486`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lon` changed from `126.9784` to `28.18783`
    • Field `contactsLocationsModule.locations.[19]city` changed from `Suwon` to `Busan`
    • Field `contactsLocationsModule.locations.[19]geoPoint.lat` changed from `37.29111` to `35.10168`
    • Field `contactsLocationsModule.locations.[19]geoPoint.lon` changed from `127.00889` to `129.03004`
    • Field `contactsLocationsModule.locations.[20]city` changed from `Taichung` to `Daegu`
    • Field `contactsLocationsModule.locations.[20]country` changed from `Taiwan` to `South Korea`
    • Field `contactsLocationsModule.locations.[20]geoPoint.lat` changed from `24.1469` to `35.87028`
    • Field `contactsLocationsModule.locations.[20]geoPoint.lon` changed from `120.6839` to `128.59111`
    • Field `contactsLocationsModule.locations.[21]city` changed from `Bangkok` to `Incheon`
    • Field `contactsLocationsModule.locations.[21]country` changed from `Thailand` to `South Korea`
    • Field `contactsLocationsModule.locations.[21]geoPoint.lat` changed from `13.75398` to `37.45646`
    • Field `contactsLocationsModule.locations.[21]geoPoint.lon` changed from `100.50144` to `126.70515`
    • Field `contactsLocationsModule.locations.[22]city` changed from `Changwat Sara Buri` to `Jinju`
    • Field `contactsLocationsModule.locations.[22]country` changed from `Thailand` to `South Korea`
    • Field `contactsLocationsModule.locations.[22]geoPoint.lat` changed from `14.53333` to `35.19278`
    • Field `contactsLocationsModule.locations.[22]geoPoint.lon` changed from `100.91667` to `128.08472`
    • Field `contactsLocationsModule.locations.[23]city` changed from `Chanthaburi` to `Seoul`
    • Field `contactsLocationsModule.locations.[23]country` changed from `Thailand` to `South Korea`
    • Field `contactsLocationsModule.locations.[23]geoPoint.lat` changed from `12.60961` to `37.566`
    • Field `contactsLocationsModule.locations.[23]geoPoint.lon` changed from `102.10447` to `126.9784`
    • Field `contactsLocationsModule.locations.[24]city` changed from `Chiang Mai` to `Suwon`
    • Field `contactsLocationsModule.locations.[24]country` changed from `Thailand` to `South Korea`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lat` changed from `18.79038` to `37.29111`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lon` changed from `98.98468` to `127.00889`
    • Field `contactsLocationsModule.locations.[25]city` changed from `Khon Kaen` to `Taichung`
    • Field `contactsLocationsModule.locations.[25]country` changed from `Thailand` to `Taiwan`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lat` changed from `16.44671` to `24.1469`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lon` changed from `102.833` to `120.6839`
    • Field `contactsLocationsModule.locations.[26]city` changed from `Lampang` to `Bangkok`
    • Field `contactsLocationsModule.locations.[26]geoPoint.lat` changed from `18.29232` to `13.75398`
    • Field `contactsLocationsModule.locations.[26]geoPoint.lon` changed from `99.49277` to `100.50144`
    • Field `contactsLocationsModule.locations.[27]city` changed from `Nakhon Nayok` to `Changwat Sara Buri`
    • Field `contactsLocationsModule.locations.[27]geoPoint.lat` changed from `14.20463` to `14.53333`
    • Field `contactsLocationsModule.locations.[27]geoPoint.lon` changed from `101.21295` to `100.91667`
    • Field `contactsLocationsModule.locations.[28]city` changed from `Nakhon Ratchasima` to `Chanthaburi`
    • Field `contactsLocationsModule.locations.[28]geoPoint.lat` changed from `14.97066` to `12.60961`
    • Field `contactsLocationsModule.locations.[28]geoPoint.lon` changed from `102.10196` to `102.10447`
    • Field `contactsLocationsModule.locations.[29]city` changed from `Phitsanulok` to `Chiang Mai`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lat` changed from `16.82481` to `18.79038`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lon` changed from `100.25858` to `98.98468`
    • Field `contactsLocationsModule.locations.[30]city` changed from `Songkhla` to `Khon Kaen`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `7.19882` to `16.44671`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `100.5951` to `102.833`
    • Field `contactsLocationsModule.locations.[31]city` changed from `Ubon Ratchathani` to `Lampang`
    • Field `contactsLocationsModule.locations.[31]geoPoint.lat` changed from `15.23844` to `18.29232`
    • Field `contactsLocationsModule.locations.[31]geoPoint.lon` changed from `104.84866` to `99.49277`
    • Field `contactsLocationsModule.locations.[32]city` changed from `Adana` to `Nakhon Nayok`
    • Field `contactsLocationsModule.locations.[32]country` changed from `Turkey (Türkiye)` to `Thailand`
    • Field `contactsLocationsModule.locations.[32]geoPoint.lat` changed from `36.98615` to `14.20463`
    • Field `contactsLocationsModule.locations.[32]geoPoint.lon` changed from `35.32531` to `101.21295`
    • Field `contactsLocationsModule.locations.[33]city` changed from `Ankara` to `Nakhon Ratchasima`
    • Field `contactsLocationsModule.locations.[33]country` changed from `Turkey (Türkiye)` to `Thailand`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lat` changed from `39.91987` to `14.97066`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lon` changed from `32.85427` to `102.10196`
    • Field `contactsLocationsModule.locations.[34]city` changed from `Edirne` to `Phitsanulok`
    • Field `contactsLocationsModule.locations.[34]country` changed from `Turkey (Türkiye)` to `Thailand`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lat` changed from `41.67719` to `16.82481`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lon` changed from `26.55597` to `100.25858`
    • Field `contactsLocationsModule.locations.[35]city` changed from `Istanbul` to `Songkhla`
    • Field `contactsLocationsModule.locations.[35]country` changed from `Turkey (Türkiye)` to `Thailand`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lat` changed from `41.01384` to `7.19882`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lon` changed from `28.94966` to `100.5951`
    • Field `contactsLocationsModule.locations.[36]city` changed from `Kocaeli` to `Ubon Ratchathani`
    • … (additional changes truncated for brevity)
  • 2026-06-02 04:04:22 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-29` to `2026-05-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-01` to `2026-06-01`
    • Field `contactsLocationsModule.locations.[2]zip` changed from `24014` to `24060`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-04` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-27` to `2026-04-29`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-30` to `2026-05-01`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'University Malaya Medical Centre', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}` to `{'facility': 'Research Site', 'city': 'Putrajaya', 'country': 'Malaysia', 'geoPoint': {'lat': 2.93527, 'lon': 101.69112}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': 'Universiti Kebangsaan Malaysia Medical Centre', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}` to `{'facility': 'Research Site', 'city': 'Pulau Pinang', 'country': 'Malaysia', 'geoPoint': {'lat': 3.55, 'lon': 102.56667}}`
    • Field `contactsLocationsModule.locations.[30]` changed from `{'facility': 'Phramongkutklao Hospital', 'city': 'Bangkok', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}` to `{'facility': 'Research Site', 'city': 'Songkhla', 'country': 'Thailand', 'geoPoint': {'lat': 7.19882, 'lon': 100.5951}}`
    • Field `contactsLocationsModule.locations.[25]` changed from `{'facility': 'Samsung Medical Center', 'city': 'Seoul', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Khon Kaen', 'country': 'Thailand', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}`
    • Field `contactsLocationsModule.locations.[28]` changed from `{'facility': 'China Medical University Hospital', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}` to `{'facility': 'Research Site', 'city': 'Nakhon Ratchasima', 'country': 'Thailand', 'geoPoint': {'lat': 14.97066, 'lon': 102.10196}}`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'Lumi Cancer Institute', 'city': 'Kingwood', 'state': 'Texas', 'zip': '77339', 'country': 'United States', 'geoPoint': {'lat': 30.05691, 'lon': -95.18349}}` to `{'facility': 'Research Site', 'city': 'Kingwood', 'state': 'Texas', 'zip': '77339', 'country': 'United States', 'geoPoint': {'lat': 30.05691, 'lon': -95.18349}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Hong Kong United Oncology Centre', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}` to `{'facility': 'Research Site', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}`
    • Field `contactsLocationsModule.locations.[36]` changed from `{'facility': 'Prapokklao Hospital', 'city': 'Chanthaburi', 'country': 'Thailand', 'geoPoint': {'lat': 12.60961, 'lon': 102.10447}}` to `{'facility': 'Research Site', 'city': 'Kocaeli', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 39.62497, 'lon': 27.51145}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': 'Hospital Pulau Pinang', 'city': 'Pulau Pinang', 'country': 'Malaysia', 'geoPoint': {'lat': 3.55, 'lon': 102.56667}}` to `{'facility': 'Research Site', 'city': 'George', 'country': 'South Africa', 'geoPoint': {'lat': -33.963, 'lon': 22.46173}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Pantai Hospital Kuala Lumpur', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}` to `{'facility': 'Research Site', 'city': 'Kuching', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}`
    • Field `contactsLocationsModule.locations.[31]` changed from `{'facility': 'Police General Hospital', 'city': 'Bangkok', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}` to `{'facility': 'Research Site', 'city': 'Ubon Ratchathani', 'country': 'Thailand', 'geoPoint': {'lat': 15.23844, 'lon': 104.84866}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Oncology and Hematology Associates of Southwest Virginia, Inc.', 'city': 'Blacksburg', 'state': 'Virginia', 'zip': '24014', 'country': 'United States', 'geoPoint': {'lat': 37.22957, 'lon': -80.41394}}` to `{'facility': 'Research Site', 'city': 'Blacksburg', 'state': 'Virginia', 'zip': '24014', 'country': 'United States', 'geoPoint': {'lat': 37.22957, 'lon': -80.41394}}`
    • Field `contactsLocationsModule.locations.[34]` changed from `{'facility': 'Vajira Hospital', 'city': 'Bangkok', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}` to `{'facility': 'Research Site', 'city': 'Edirne', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 41.67719, 'lon': 26.55597}}`
    • Field `contactsLocationsModule.locations.[16]` changed from `{'facility': "St Luke's Medical Center", 'city': 'Manila', 'country': 'Philippines', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}` to `{'facility': 'Research Site', 'city': 'Incheon', 'country': 'South Korea', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}`
    • Field `contactsLocationsModule.locations.[17]` changed from `{'facility': 'Exellentis Clinical Trial Consultants', 'city': 'George', 'country': 'South Africa', 'geoPoint': {'lat': -33.963, 'lon': 22.46173}}` to `{'facility': 'Research Site', 'city': 'Jinju', 'country': 'South Korea', 'geoPoint': {'lat': 35.19278, 'lon': 128.08472}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'Hospital Tengku Ampuan Afzan', 'city': 'Kuantan', 'country': 'Malaysia', 'geoPoint': {'lat': 3.8077, 'lon': 103.326}}` to `{'facility': 'Research Site', 'city': 'Davao City', 'country': 'Philippines', 'geoPoint': {'lat': 7.07306, 'lon': 125.61278}}`
    • Field `contactsLocationsModule.locations.[26]` changed from `{'facility': "The Catholic University of Korea Eunpyeong St. Mary's Hospital", 'city': 'Seoul', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Lampang', 'country': 'Thailand', 'geoPoint': {'lat': 18.29232, 'lon': 99.49277}}`
    • Field `contactsLocationsModule.locations.[37]` changed from `{'facility': 'Maharaj Nakorn Chiang Mai Hospital', 'city': 'Chiang Mai', 'country': 'Thailand', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}` to `{'facility': 'Research Site', 'city': 'Hanoi', 'country': 'Vietnam', 'geoPoint': {'lat': 21.0245, 'lon': 105.84117}}`
    • Field `contactsLocationsModule.locations.[19]` changed from `{'facility': 'University of Pretoria Medical Oncology', 'city': 'Pretoria', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}` to `{'facility': 'Research Site', 'city': 'Suwon', 'country': 'South Korea', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'Hospital Sultan Ismail', 'city': 'Johor Bahru', 'country': 'Malaysia', 'geoPoint': {'lat': 1.4655, 'lon': 103.7578}}` to `{'facility': 'Research Site', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Metro Davao Medical And Research Center Inc.', 'city': 'Davao City', 'country': 'Philippines', 'geoPoint': {'lat': 7.07306, 'lon': 125.61278}}` to `{'facility': 'Research Site', 'city': 'Pretoria', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}`
    • Field `contactsLocationsModule.locations.[33]` changed from `{'facility': 'Siriraj Hospital', 'city': 'Bangkok', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}` to `{'facility': 'Research Site', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}`
    • Field `contactsLocationsModule.locations.[38]` changed from `{'facility': 'Nakornping Hospital', 'city': 'Chiang Mai', 'country': 'Thailand', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}` to `{'facility': 'Research Site', 'city': 'Huế', 'country': 'Vietnam', 'geoPoint': {'lat': 16.4619, 'lon': 107.59546}}`
    • Field `contactsLocationsModule.locations.[23]` changed from `{'facility': 'Gyeongsang National University Hospital', 'city': 'Jinju', 'country': 'South Korea', 'geoPoint': {'lat': 35.19278, 'lon': 128.08472}}` to `{'facility': 'Research Site', 'city': 'Chanthaburi', 'country': 'Thailand', 'geoPoint': {'lat': 12.60961, 'lon': 102.10447}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Humanity and Health Clinical Trial Centre', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}` to `{'facility': 'Research Site', 'city': 'Johor Bahru', 'country': 'Malaysia', 'geoPoint': {'lat': 1.4655, 'lon': 103.7578}}`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Philippine General Hospital', 'city': 'Manila', 'country': 'Philippines', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}` to `{'facility': 'Research Site', 'city': 'Daegu', 'country': 'South Korea', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}`
    • Field `contactsLocationsModule.locations.[20]` changed from `{'facility': 'Wilgers Oncology Centre', 'city': 'Pretoria', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}` to `{'facility': 'Research Site', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}`
    • Field `contactsLocationsModule.locations.[11]` changed from `{'facility': 'Hospital Umum Sarawak', 'city': 'Kuching', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}` to `{'facility': 'Research Site', 'city': 'Manila', 'country': 'Philippines', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}`
    • Field `contactsLocationsModule.locations.[18]` changed from `{'facility': 'Cancercare PE', 'city': 'Johannesburg', 'country': 'South Africa', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[32]` chang
  • 2026-03-31 02:31:36 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-06` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-09` to `2026-03-30`
  • 2026-03-10 02:06:11 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-09` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-15` to `2026-03-09`
    • Field `contactsLocationsModule.locations.[1]facility` changed from `General hospital of Athens, chest diseases Sotiria` to `Lumi Cancer Institute`
    • Field `contactsLocationsModule.locations.[1]city` changed from `Athens` to `Kingwood`
    • Field `contactsLocationsModule.locations.[1]country` changed from `Greece` to `United States`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lat` changed from `37.98376` to `30.05691`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lon` changed from `23.72784` to `-95.18349`
    • Field `contactsLocationsModule.locations.[0]facility` changed from `Hope and Healing Cancer Service` to `Oncology and Hematology Associates of Southwest Virginia, Inc.`
    • Field `contactsLocationsModule.locations.[0]city` changed from `Hinsdale` to `Blacksburg`
    • Field `contactsLocationsModule.locations.[0]state` changed from `Illinois` to `Virginia`
    • Field `contactsLocationsModule.locations.[0]zip` changed from `60521` to `24014`
    • Field `contactsLocationsModule.locations.[0]geoPoint.lat` changed from `41.80086` to `37.22957`
    • Field `contactsLocationsModule.locations.[0]geoPoint.lon` changed from `-87.93701` to `-80.41394`
    • Field `contactsLocationsModule.locations.[23]facility` changed from `Metro Davao Medical and Research Centre` to `Metro Davao Medical And Research Center Inc.`
    • Field `contactsLocationsModule.locations.[24]facility` changed from `Makati Medical Centre` to `St Luke's Medical Center`
    • Field `contactsLocationsModule.locations.[36]facility` changed from `Keimyung University Dongsan Hospital` to `Keimyung University`
    • Field `contactsLocationsModule.locations.[87]facility` changed from `Kocaeli Universitiesi Tip Fakultesi` to `Goztepe Prof. Dr. Suleyman Yalcin City Hospital`
    • New field added: `root['contactsLocationsModule']['locations'][1]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][1]['zip']`

NCT07115043

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-10` to `2026-07-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-11` to `2026-07-07`
    • Field `contactsLocationsModule.locations.[10]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-06-12 04:04:21 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-22` to `2026-06-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-23` to `2026-06-11`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-16` to `2026-04-22`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-17` to `2026-04-23`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-04` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-05` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[2]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-10 07:03:45 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-18` to `2026-02-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-19` to `2026-02-05`
    • Field `contactsLocationsModule.locations.[1]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05904886

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[157]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[157]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[157]geoPoint.lon` changed from `121.3187` to `121.29696`

NCT03739710

  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[25]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04791839

  • 2026-06-09 03:36:38 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-04` to `2026-06-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-06` to `2026-06-08`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-05`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-04-30` to `2026-10-31`
    • Field `statusModule.completionDateStruct.date` changed from `2030-06-30` to `2030-12-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-04` to `2026-05-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-05` to `2026-05-06`

NCT05020912

  • 2026-06-02 04:04:22 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-05`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-25` to `2026-05-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-26` to `2026-06-01`
    • Field `designModule.enrollmentInfo.count` changed from `28` to `18`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic
      • Must have at least one BCC tumor eligible for removal by surgical excision
      • Men and women of any ethnic group are eligible
      • Must provide informed consent to participate
    • Exclusion Criteria:
      • Pregnant or breastfeeding
      • Currently being treated for other cancers with medical or radiation therapy
      • Known hypersensitivity to 5-aminolevulinic acid (ALA)
      • History of a photosensitivity disease, e.g.,porphyria cutanea tarda` to `Inclusion Criteria
      • Must be an adult parcticpant (\> 18 yrs) who is scheduled to undergo BCC surgery (via Mohs surgery, ED\&C, or standard elliptical excision) within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic.
      • Must have at least one BCC tumor eligible for surgical removal
      • Participants of any ethnic group are eligible for this trial.
      • Must provide informed consent to participate in the trial.
    • Exclusion Criteria
      • Pregnant or breastfeeding
      • Currently being treated for other cancers with medical or radiation therapy
      • Known hypersensitivity to 5-aminolevulinic acid
      • History of a photosensitivity disease, e.g., porphyria cutanea tarda`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT06334406

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT05123482

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-16` to `2026-07-15`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-17` to `2026-07-16`
    • Field `contactsLocationsModule.locations.[16]status` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
  • 2026-06-18 04:04:37 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-15` to `2026-06-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-18` to `2026-06-17`
    • Field `contactsLocationsModule.locations.[38]city` changed from `Rozzano` to `Milan`
    • Field `contactsLocationsModule.locations.[38]zip` changed from `20089` to `20159`
    • Field `contactsLocationsModule.locations.[38]geoPoint.lat` changed from `45.38193` to `42.78235`
    • Field `contactsLocationsModule.locations.[38]geoPoint.lon` changed from `9.1559` to `12.59836`
    • Field `contactsLocationsModule.locations.[65]status` changed from `RECRUITING` to `COMPLETED`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-20` to `2026-05-15`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-23` to `2026-05-18`
    • Field `contactsLocationsModule.locations.[4]status` changed from `ACTIVE_NOT_RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[31]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[31]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `contactsLocationsModule.locations.[57]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[61]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-03-24 02:11:01 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-11` to `2026-03-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-13` to `2026-03-23`
    • Field `contactsLocationsModule.locations.[26]status` changed from `SUSPENDED` to `TERMINATED`
  • 2026-02-16 21:08:10 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-02` to `2026-02-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-08` to `2026-02-13`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[1]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[18]status` changed from `WITHDRAWN` to `NOT_YET_RECRUITING`
    • Field `contactsLocationsModule.locations.[18]city` changed from `South Brisbane` to `Taichung`
    • Field `contactsLocationsModule.locations.[18]zip` changed from `4101` to `40705`
    • Field `contactsLocationsModule.locations.[18]country` changed from `Australia` to `Taiwan`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lat` changed from `-27.48034` to `24.1469`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lon` changed from `153.02049` to `120.6839`

NCT07161414

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-09` to `2026-07-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-10` to `2026-07-09`
  • 2026-06-11 04:04:07 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-07` to `2026-06-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-08` to `2026-06-10`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-08` to `2026-05-07`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-09` to `2026-05-08`
  • 2026-04-10 02:39:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-16` to `2026-04-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-17` to `2026-04-09`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-23` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[6]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[8]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05702229

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-16` to `2026-05-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-18` to `2026-05-14`
    • Field `contactsLocationsModule.locations.[39]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-03-19 02:24:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-03` to `2027-11-30`
    • Field `statusModule.completionDateStruct.date` changed from `2027-09-28` to `2029-05-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-14` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-17` to `2026-03-18`
    • Field `descriptionModule.detailedDescription` changed from `Approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy.` to `Approximately 360 participants will be assigned across 4 substudies, with approximately 60 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy/cohort.`
    • Field `designModule.enrollmentInfo.count` changed from `240` to `163`
    • Field `armsInterventionsModule.armGroups.[3]label` changed from `Substudy 4` to `Substudy 4, Cohort 4a1`
    • Field `armsInterventionsModule.armGroups.[3]description` changed from `AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine` to `Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil or capecitabine`
    • Field `armsInterventionsModule.armGroups.[5]label` changed from `Substudy 6` to `Substudy 4, Cohort 4a2`
    • Field `armsInterventionsModule.armGroups.[5]description` changed from `AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine` to `Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil`
    • Field `armsInterventionsModule.armGroups.[4]label` changed from `Substudy 5` to `Substudy 4, Cohort 4b`
    • Field `armsInterventionsModule.armGroups.[4]description` changed from `AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)` to `Sonesitatug vedotin (AZD0901) plus capecitabine`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • 18 years or older at the time of signing the ICF.
      • Body weight \> 35 kg.
      • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
      • Has measurable target disease assessed by the Investigator based on RECIST 1.1.
      • ECOG PS zero or one.
      • Life expectancy of at least 12 weeks.
      • Adequate organ and bone marrow function.
      • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.
    • Exclusion Criteria:
      • Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
      • Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
      • Participants with ascites which cannot be controlled with appropriate interventions.
      • Active infectious diseases, including tuberculosis, HIV infection, or hepatitis A/B/C.
      • Uncontrolled intercurrent illness.
      • Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
      • History of another primary malignancy.
      • Previous treatment with an immune-oncology agent.
      • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).` to `Inclusion Criteria:
      • 18 years or older at the time of signing the ICF.
      • Body weight \> 35 kg.
      • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
      • Has measurable target disease assessed by the Investigator based on RECIST 1.1.
      • ECOG PS zero or one.
      • Life expectancy of at least 12 weeks.
      • Adequate organ and bone marrow function.
      • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 i s open for recruitment.
    • Exclusion Criteria:
      • Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
      • Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
      • Participants with ascites which cannot be controlled with appropriate interventions.
      • Active infectious diseases, including tuberculosis, HIV infection, or hepatitis B/C.
      • Uncontrolled intercurrent illness.
      • Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
      • History of another primary malignancy.
      • Previous treatment with an immune-oncology agent.
      • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 2', 'Substudy 4']}` to `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 2', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'FOLFOX', 'description': '5-fluorouracil 400 mg/m\\^2 IV, oxaliplatin 85 mg/m\\^2, leucovorin 400 mg/m\\^2 (or levoleucovorin 200 mg/m\\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\\^2 IV 24 h day 1-2', 'armGroupLabels': ['Substudy 1', 'Substudy 2', 'Substudy 5']}` to `{'type': 'DRUG', 'name': 'FOLFOX', 'description': '5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)', 'armGroupLabels': ['Substudy 1', 'Substudy 2']}`
    • Field `armsInterventionsModule.interventions.[6]` changed from `{'type': 'DRUG', 'name': '5-Fluorouracil', 'description': '5-FU, IV infusion, Q3W', 'armGroupLabels': ['Substudy 3', 'Substudy 4', 'Substudy 6']}` to `{'type': 'DRUG', 'name': 'Capecitabine', 'description': 'Oral take', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4b']}`
    • Field `armsInterventionsModule.armGroups.[4]interventionNames.[1]` changed from `Drug: XELOX` to `Drug: Capecitabine`
    • Field `armsInterventionsModule.interventions.[5]` changed from `{'type': 'DRUG', 'name': 'AZD0901', 'description': 'an anti Claudin18.2 ADC; IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4', 'Substudy 6']}` to `{'type': 'DRUG', 'name': '5-Fluorouracil', 'description': '5-FU, IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2']}`
    • Field `armsInterventionsModule.armGroups.[5]interventionNames.[0]` changed from `Drug: AZD7789` to `Drug: Rilvegostomig`
    • Field `armsInterventionsModule.armGroups.[4]interventionNames.[0]` changed from `Drug: FOLFOX` to `Drug: AZD0901`
    • Field `armsInterventionsModule.interventions.[4]` changed from `{'type': 'DRUG', 'name': 'AZD7789', 'description': 'an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 5', 'Substudy 6']}` to `{'type': 'DRUG', 'name': 'AZD0901', 'description': 'an anti Claudin18.2 ADC; IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2', 'Substudy 4, Cohort 4b']}`
    • Field `armsInterventionsModule.interventions.[3]` changed from `{'type': 'DRUG', 'name': 'XELOX', 'description': 'capecitabine 1000 mg/m\\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\\^2, day 1', 'armGroupLabels': ['Substudy 1', 'Substudy 2', 'Substudy 5']}` to `{'type': 'DRUG', 'name': 'XELOX', 'description': 'capecitabine and oxaliplatin', 'armGroupLabels': ['Substudy 1', 'Substudy 2']}`

NCT04836507

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients` to `Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients`
    • Field `identificationModule.officialTitle` changed from `An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma` to `An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia`
    • Field `statusModule.statusVerifiedDate` changed from `2021-04` to `2026-06`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2023-05` to `2030-08-15`
    • Field `statusModule.completionDateStruct.date` changed from `2028-02` to `2030-09-26`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2021-04-29` to `2026-06-29`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2021-05-03` to `2026-07-01`
    • Field `descriptionModule.briefSummary` changed from `This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma.` to `This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.`
    • Field `armsInterventionsModule.interventions.[0]description` changed from `A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.` to `Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
    • Cohort B :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 1.5 x 10\^6 anti-CD19 CAR T cells/kg.`
    • Field `outcomesModule.primaryOutcomes.[1]measure` changed from `Phase 2 Pivotal Study: Overall Response Rate (ORR)` to `Phase 2 Pivotal Study: Cohort A : Overall Response Rate (ORR) Cohort B : Overall Complete Remission Rate (OCR)`
    • Field `outcomesModule.primaryOutcomes.[1]description` changed from `ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014).` to `Cohort A : ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014).
    • Cohort B : OCR is defined as the incidence of either a complete Remission (CR) or a Complete Remission with incomplete hematologic recovery (CRi) per the ALL Response Criteria.`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      1. ≥ 19 years of age and provided written informed consent
      1. Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017
      • Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)
      • High-grade B-cell lymphoma, not otherwise specified
      • High-grade B-cell lymphoma with double-hit/triple-hit
      • Primary mediastinal large B cell lymphoma
      1. Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab, anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT.
      1. At least one measurable lesion (Long diameter ≥ 1.5cm)
      1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
      1. Adequate renal and hepatic functions based on the laboratory test results
      • Total Bilirubin ≤ 2.0mg/dL w` to `Cohort A:
    • Inclusion Criteria:
      1. ≥ 19 years of age and provided written informed consent
      1. Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017
      • Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)
      • High-grade B-cell lymphoma, not otherwise specified
      • High-grade B-cell lymphoma with double-hit/triple-hit
      • Primary mediastinal large B cell lymphoma
      1. Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab, anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT.
      1. At least one measurable lesion (Long diameter ≥ 1.5cm)
      1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
      1. Adequate renal and hepatic functions based on the laboratory test results
      • Total Bilirubin ≤`
  • 2026-06-16 04:16:42 (Trial Update)
    • Minor formatting updates.

NCT05775159

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-16` to `2026-07-01`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-17` to `2026-07-02`
    • Field `contactsLocationsModule.locations.[1]city` changed from `Costa Mesa` to `Los Angeles`
    • Field `contactsLocationsModule.locations.[1]zip` changed from `92627` to `90089`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lat` changed from `33.64113` to `34.05223`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lon` changed from `-117.91867` to `-118.24368`
    • Field `contactsLocationsModule.locations.[2]city` changed from `Los Angeles` to `Orange`
    • Field `contactsLocationsModule.locations.[2]zip` changed from `90089` to `92868`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lat` changed from `34.05223` to `33.78779`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lon` changed from `-118.24368` to `-117.85311`
    • Field `contactsLocationsModule.locations.[3]city` changed from `Orange` to `Kansas City`
    • Field `contactsLocationsModule.locations.[3]state` changed from `California` to `Kansas`
    • Field `contactsLocationsModule.locations.[3]zip` changed from `92868` to `66103`
    • Field `contactsLocationsModule.locations.[3]geoPoint.lat` changed from `33.78779` to `39.11417`
    • Field `contactsLocationsModule.locations.[3]geoPoint.lon` changed from `-117.85311` to `-94.62746`
    • Field `contactsLocationsModule.locations.[4]city` changed from `Miami Beach` to `New York`
    • Field `contactsLocationsModule.locations.[4]state` changed from `Florida` to `New York`
    • Field `contactsLocationsModule.locations.[4]zip` changed from `33140` to `10065`
    • Field `contactsLocationsModule.locations.[4]geoPoint.lat` changed from `25.79065` to `40.71427`
    • Field `contactsLocationsModule.locations.[4]geoPoint.lon` changed from `-80.13005` to `-74.00597`
    • Field `contactsLocationsModule.locations.[5]city` changed from `Dyer` to `Beijing`
    • Field `contactsLocationsModule.locations.[5]zip` changed from `46311` to `100050`
    • Field `contactsLocationsModule.locations.[5]country` changed from `United States` to `China`
    • Field `contactsLocationsModule.locations.[5]geoPoint.lat` changed from `41.4942` to `39.9075`
    • Field `contactsLocationsModule.locations.[5]geoPoint.lon` changed from `-87.52171` to `116.39723`
    • Field `contactsLocationsModule.locations.[6]city` changed from `Kansas City` to `Beijing`
    • Field `contactsLocationsModule.locations.[6]zip` changed from `66103` to `100142`
    • Field `contactsLocationsModule.locations.[6]country` changed from `United States` to `China`
    • Field `contactsLocationsModule.locations.[6]geoPoint.lat` changed from `39.11417` to `39.9075`
    • Field `contactsLocationsModule.locations.[6]geoPoint.lon` changed from `-94.62746` to `116.39723`
    • Field `contactsLocationsModule.locations.[7]city` changed from `New York` to `Beijing`
    • Field `contactsLocationsModule.locations.[7]zip` changed from `10065` to `101100`
    • Field `contactsLocationsModule.locations.[7]country` changed from `United States` to `China`
    • Field `contactsLocationsModule.locations.[7]geoPoint.lat` changed from `40.71427` to `39.9075`
    • Field `contactsLocationsModule.locations.[7]geoPoint.lon` changed from `-74.00597` to `116.39723`
    • Field `contactsLocationsModule.locations.[8]city` changed from `Dallas` to `Chengdu`
    • Field `contactsLocationsModule.locations.[8]zip` changed from `75251` to `610000`
    • Field `contactsLocationsModule.locations.[8]country` changed from `United States` to `China`
    • Field `contactsLocationsModule.locations.[8]geoPoint.lat` changed from `32.78306` to `30.66667`
    • Field `contactsLocationsModule.locations.[8]geoPoint.lon` changed from `-96.80667` to `104.06667`
    • Field `contactsLocationsModule.locations.[9]city` changed from `Fairfax` to `Chengdu`
    • Field `contactsLocationsModule.locations.[9]zip` changed from `22031` to `610041`
    • Field `contactsLocationsModule.locations.[9]country` changed from `United States` to `China`
    • Field `contactsLocationsModule.locations.[9]geoPoint.lat` changed from `38.84622` to `30.66667`
    • Field `contactsLocationsModule.locations.[9]geoPoint.lon` changed from `-77.30637` to `104.06667`
    • Field `contactsLocationsModule.locations.[10]city` changed from `Beijing` to `Chongqing`
    • Field `contactsLocationsModule.locations.[10]zip` changed from `100050` to `400030`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lat` changed from `39.9075` to `29.56026`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lon` changed from `116.39723` to `106.55771`
    • Field `contactsLocationsModule.locations.[11]city` changed from `Beijing` to `Fuzhou`
    • Field `contactsLocationsModule.locations.[11]zip` changed from `100142` to `350007`
    • Field `contactsLocationsModule.locations.[11]geoPoint.lat` changed from `39.9075` to `26.06139`
    • Field `contactsLocationsModule.locations.[11]geoPoint.lon` changed from `116.39723` to `119.30611`
    • Field `contactsLocationsModule.locations.[12]city` changed from `Beijing` to `Guangzhou`
    • Field `contactsLocationsModule.locations.[12]zip` changed from `101100` to `510060`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lat` changed from `39.9075` to `23.11667`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lon` changed from `116.39723` to `113.25`
    • Field `contactsLocationsModule.locations.[13]city` changed from `Chengdu` to `Guangzhou`
    • Field `contactsLocationsModule.locations.[13]zip` changed from `610000` to `510515`
    • Field `contactsLocationsModule.locations.[13]geoPoint.lat` changed from `30.66667` to `23.11667`
    • Field `contactsLocationsModule.locations.[13]geoPoint.lon` changed from `104.06667` to `113.25`
    • Field `contactsLocationsModule.locations.[14]city` changed from `Chengdu` to `Harbin`
    • Field `contactsLocationsModule.locations.[14]zip` changed from `610041` to `150081`
    • Field `contactsLocationsModule.locations.[14]geoPoint.lat` changed from `30.66667` to `45.75`
    • Field `contactsLocationsModule.locations.[14]geoPoint.lon` changed from `104.06667` to `126.65`
    • Field `contactsLocationsModule.locations.[15]city` changed from `Chongqing` to `Nanning`
    • Field `contactsLocationsModule.locations.[15]zip` changed from `400030` to `530021`
    • Field `contactsLocationsModule.locations.[15]geoPoint.lat` changed from `29.56026` to `22.81667`
    • Field `contactsLocationsModule.locations.[15]geoPoint.lon` changed from `106.55771` to `108.31667`
    • Field `contactsLocationsModule.locations.[16]city` changed from `Fuzhou` to `Shanghai`
    • Field `contactsLocationsModule.locations.[16]zip` changed from `350007` to `200032`
    • Field `contactsLocationsModule.locations.[16]geoPoint.lat` changed from `26.06139` to `31.22222`
    • Field `contactsLocationsModule.locations.[16]geoPoint.lon` changed from `119.30611` to `121.45806`
    • Field `contactsLocationsModule.locations.[17]city` changed from `Guangzhou` to `Hong Kong`
    • Field `contactsLocationsModule.locations.[17]zip` changed from `510060` to `999077`
    • Field `contactsLocationsModule.locations.[17]country` changed from `China` to `Hong Kong`
    • Field `contactsLocationsModule.locations.[17]geoPoint.lat` changed from `23.11667` to `22.27832`
    • Field `contactsLocationsModule.locations.[17]geoPoint.lon` changed from `113.25` to `114.17469`
    • Field `contactsLocationsModule.locations.[18]city` changed from `Guangzhou` to `Shatin`
    • Field `contactsLocationsModule.locations.[18]zip` changed from `510515` to `00000`
    • Field `contactsLocationsModule.locations.[18]country` changed from `China` to `Hong Kong`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lat` changed from `23.11667` to `22.38333`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lon` changed from `113.25` to `114.18333`
    • Field `contactsLocationsModule.locations.[19]city` changed from `Harbin` to `Florence`
    • Field `contactsLocationsModule.locations.[19]zip` changed from `150081` to `50134`
    • Field `contactsLocationsModule.locations.[19]country` changed from `China` to `Italy`
    • Field `contactsLocationsModule.locations.[19]geoPoint.lat` changed from `45.75` to `43.77925`
    • Field `contactsLocationsModule.locations.[19]geoPoint.lon` changed from `126.65` to `11.24626`
    • Field `contactsLocationsModule.locations.[20]city` changed from `Hefei` to `Milan`
    • Field `contactsLocationsModule.locations.[20]zip` changed from `230001` to `20132`
    • Field `contactsLocationsModule.locations.[20]country` changed from `China` to `Italy`
    • Field `contactsLocationsModule.locations.[20]geoPoint.lat` changed from `31.86389` to `42.78235`
    • Field `contactsLocationsModule.locations.[20]geoPoint.lon` changed from `117.28083` to `12.59836`
    • Field `contactsLocationsModule.locations.[21]city` changed from `Hefei` to `Naples`
    • Field `contactsLocationsModule.locations.[21]zip` changed from `230022` to `80131`
    • Field `contactsLocationsModule.locations.[21]country` changed from `China` to `Italy`
    • Field `contactsLocationsModule.locations.[21]geoPoint.lat` changed from `31.86389` to `40.85216`
    • Field `contactsLocationsModule.locations.[21]geoPoint.lon` changed from `117.28083` to `14.26811`
    • … (additional changes truncated for brevity)
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-16` to `2026-04-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-18` to `2026-04-17`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `contactsLocationsModule.locations.[55]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[55]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[55]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[33]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-02-19 01:00:01 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-12` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-13` to `2026-02-18`

NCT06860815

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-05`
    • Field `statusModule.startDateStruct.date` changed from `2026-04-01` to `2026-01-30`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-27` to `2026-05-18`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-28` to `2026-05-20`

NCT05574335

  • 2026-07-29 02:40:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-06`
    • Field `statusModule.startDateStruct.date` changed from `2023-04-26` to `2023-05-18`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-10` to `2026-06-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-11` to `2026-07-28`
    • Field `outcomesModule.primaryOutcomes.[0]measure` changed from `Number of Participants with a T cell phenotype signature response` to `Number of Participants With a T Cell Phenotype Signature Response`
    • Field `outcomesModule.primaryOutcomes.[0]description` changed from `Evaluating four siplizumab dosing regimens for induction of a T cell phenotype signature is based on a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem and a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood.
    • The two criteria will be evaluated at weeks 2, 4, 8, and 12. An individual who achieves both signature criteria at any time point on or before week 12 is counted as having the signature response. Both criteria do not need to be achieved at the same time point.` to `A participant is defined as achieving a T Cell phenotype signature response if the participant experiences both a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood and a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem. The two criteria will be evaluated at weeks 2, 4, 8, and 12. Both criteria do not need to be achieved at the same time point.`
    • Field `outcomesModule.primaryOutcomes.[0]timeFrame` changed from `From week 0 (baseline) to week 12` to `Week 0 to Week 12`
    • Field `outcomesModule.secondaryOutcomes.[0]measure` changed from `Frequency of Adverse Events (AEs) in all siplizumab dosing arms` to `Frequency of Adverse Events (AEs) in All Siplizumab Dosing Arms`
    • Field `outcomesModule.secondaryOutcomes.[1]measure` changed from `Mixed Meal Tolerance Test (MMTT)-stimulated mean 2-hour C-peptide AUC` to `Mixed Meal Tolerance Test (MMTT)-Stimulated Mean 2-hour C-peptide AUC`
    • Field `outcomesModule.secondaryOutcomes.[2]measure` changed from `Insulin use (U/kg/day)` to `Insulin Use (U/kg/Day)`
    • New field added: `root['statusModule']['resultsFirstSubmitDate']`
    • New field added: `root['statusModule']['resultsFirstSubmitQcDate']`
    • New field added: `root['statusModule']['resultsFirstPostDateStruct']`
  • 2026-02-12 14:01:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-05` to `2026-02-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-06` to `2026-02-11`

NCT06302556

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[2]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-03 00:59:12 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT04693234

  • 2026-06-06 03:35:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[17]city` changed from `Jilin` to `Jilin City`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `referencesModule.references.[0]` changed from `{'pmid': '40411966', 'type': 'BACKGROUND', 'citation': 'Lee JY, Boonyapipat S, Yuan G, Kim HS, Lee JW, Wang L, Wang T, Wang D, Yao D, Liu H, Chang CL, Andabekov TT, Zhang X, Wang W, Kim YM, Sinielnikov IV, Wang K, Gao Y, Mu X, Wu L. AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. Gynecol Oncol. 2025 Jul;198:25-32. doi: 10.1016/j.ygyno.2025.04.579. Epub 2025 May 23.'}` to `{'type': 'BACKGROUND', 'citation': 'Wu L, Wang PH, Hsiao SY, et al. AdvanTIG-202: A phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer (333). Gynecol Oncol. 2022;166:S172. doi:10.1016/S0090-8258(22)01555-4'}`

NCT03563716

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-04`
    • Field `statusModule.completionDateStruct.date` changed from `2025-11-24` to `2025-11-14`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-30` to `2026-04-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-20` to `2026-05-04`
    • Field `contactsLocationsModule.locations.[39]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lon` changed from `121.3187` to `121.29696`
    • Field `outcomesModule.primaryOutcomes.[0]` changed from `{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR, defined as a complete response (CR) or partial response (PR) on two consecutive occasions \\>/=4 weeks apart, as determined by the investigator according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.', 'timeFrame': 'From baseline until a total of 80 progression free survival (PFS) events have occurred (up to approximately 11 months)'}` to `{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target lesions) must have a reduction in short axis to \\<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.', 'timeFrame': 'From baseline until a total of 80 progression-free survival (PFS) events have occurred (up to approximately 11 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[5]` changed from `{'measure': 'Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)', 'timeFrame': 'Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)'}` to `{'measure': 'Number of Participants With Treatment-Emergent Anti-drug Antibodies (ADAs) to Tiragolumab', 'description': 'Participants who received tiragolumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following tiragolumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.', 'timeFrame': 'Up to approximately 36 months'}`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Percentage of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'Up to 6 years'}` to `{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'From initiation of study drug up to approximately 83.7 months'}`
    • Field `outcomesModule.secondaryOutcomes.[1]` changed from `{'measure': 'Overall Survival (OS)', 'description': 'OS, defined as the time from randomization to death from any cause.', 'timeFrame': 'Up to 6 years'}` to `{'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the time from randomization to death from any cause. KM methodology was used to estimate the median OS.', 'timeFrame': 'Up to approximately 36 months'}`
    • Field `outcomesModule.primaryOutcomes.[1]` changed from `{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).', 'timeFrame': 'From baseline until a total of 80 PFS events have occurred (up to approximately 11 months)'}` to `{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline) or unequivocal progression of existing non-target lesions. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥5 mm. Kaplan-Meier (KM) methodology was used to estimate the median PFS.', 'timeFrame': 'From baseline until a total of 80 PFS events have occurred (up to approximately 11 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[3]` changed from `{'measure': 'Serum Concentrations of Tiragolumab', 'timeFrame': 'Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)'}` to `{'measure': 'Minimum Serum Concentration (Cmin) of Tiragolumab', 'timeFrame': 'Predose on Day 1 of Cycles 1, 3 and 11 (Cycle length = 21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[0]` changed from `{'measure': 'Duration of Objective Response (DOR)', 'description': 'DOR, defined as the time from the first occurrence of a documented objective response (CR or PR) to disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).', 'timeFrame': 'Up to 6 years'}` to `{'measure': 'Duration of Objective Response (DOR)', 'description': 'DOR was defined as the time from the first occurrence of a documented objective response (OR) (CR or PR) to PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. CR was defined as the disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target lesions) must have a reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline) or unequivocal progression of existing non-target lesions. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥5 mm. KM methodology was used to`
    • Field `outcomesModule.secondaryOutcomes.[4]` changed from `{'measure': 'Serum Concentrations of Atezolizumab', 'timeFrame': 'Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)'}` to `{'measure': 'Cmin of Atezolizumab', 'timeFrame': 'Predose on Day 1 of Cycles 1, 3 and 11 (Cycle length = 21 days)'}`

NCT04732494

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[32]geoPoint.lat` changed from `26.6636` to `25.93504`
    • Field `contactsLocationsModule.locations.[32]geoPoint.lon` changed from `114.148` to `116.17968`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lat` changed from `28.26048` to `27.60412`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lon` changed from `103.93137` to `103.50288`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lat` changed from `39.46731` to `37.92189`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lon` changed from `115.13706` to `112.22494`
    • Field `contactsLocationsModule.locations.[36]geoPoint.lat` changed from `39.46731` to `37.92189`
    • Field `contactsLocationsModule.locations.[36]geoPoint.lon` changed from `115.13706` to `112.22494`
    • Field `contactsLocationsModule.locations.[37]geoPoint.lat` changed from `39.46731` to `37.92189`
    • Field `contactsLocationsModule.locations.[37]geoPoint.lon` changed from `115.13706` to `112.22494`
    • Field `contactsLocationsModule.locations.[38]geoPoint.lat` changed from `34.01329` to `29.08114`
    • Field `contactsLocationsModule.locations.[38]geoPoint.lon` changed from `118.87165` to `120.41732`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lat` changed from `34.01329` to `29.08114`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lon` changed from `118.87165` to `120.41732`
    • Field `contactsLocationsModule.locations.[40]geoPoint.lat` changed from `33.9693` to `32.92741`
    • Field `contactsLocationsModule.locations.[40]geoPoint.lon` changed from `118.85431` to `120.18021`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `contactsLocationsModule.locations.[44]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[44]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `contactsLocationsModule.locations.[50]geoPoint.lat` changed from `22.4143` to `25.3238`
    • Field `contactsLocationsModule.locations.[50]geoPoint.lon` changed from `108.78745` to `105.583`
    • Field `contactsLocationsModule.locations.[51]geoPoint.lat` changed from `22.4143` to `25.3238`
    • Field `contactsLocationsModule.locations.[51]geoPoint.lon` changed from `108.78745` to `105.583`
    • Field `contactsLocationsModule.locations.[79]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lon` changed from `121.3187` to `121.29696`

NCT05645692

  • 2026-07-29 02:41:00 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-28` to `2026-07-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-29` to `2026-07-28`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-28` to `2026-04-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-30` to `2026-04-29`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[30]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[24]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04457778

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2023-11` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2023-12-07` to `2026-04-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2023-12-08` to `2026-05-04`
    • Field `descriptionModule.briefSummary` changed from `The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks (Q2W) regimen and the every 3 weeks (Q3W) regimen and of M6223 combined with bintrafusp alfa (Part 1B) for Q2W regimen in participants with metastatic or locally advanced solid unresectable tumors.` to `The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks (Q2W) regimen and the every 3 weeks (Q3W) regimen and of M6223 combined with bintrafusp alfa (Part 1B) for Q2W regimen in participants with metastatic or locally advanced solid unresectable tumors.`
    • Field `outcomesModule.primaryOutcomes.[4]` changed from `{'measure': 'Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Electrocardiogram Findings', 'timeFrame': 'Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)'}` to `{'measure': 'Part 1A and 1B: Number of Participants With Clinically Meaningful Change From Baseline in Electrocardiogram (ECG)', 'description': 'Number of participants with clinically significant change from baseline in ECG parameters were reported. Clinical Significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Respiratory Rate, Pulse Rate, QRS, QT and QTcB calculated by the Bazett formula.', 'timeFrame': 'Approximately 2 years 11 months'}`
    • Field `outcomesModule.secondaryOutcomes.[5]` changed from `{'measure': 'Part 1A and Part 1B: Time to Reach Maximum Serum Concentration (Tmax) of M6223', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)'}` to `{'measure': 'Part 1A and Part 1B: Time to Reach Maximum Serum Concentration (Tmax) of M6223', 'description': 'Time taken to reach maximum concentration of M66223 after admistration is reported.', 'timeFrame': 'Cycle 1 and 2: Day 1 (-2h, EOI, 4-6h), Day 2 (25-31h), Day 5 (±1h), Day 8 (±1h); Cycle 3 to end of treatment: Day 1 (-2h pre-dose only)'}`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Part 1A and Part 1B: Area Under Serum Concentration-Time Curve Over a Dosing Interval From Time Zero to Tau (τ) (AUCτ) of M6223', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)'}` to `{'measure': 'Part 1A and Part 1B: Area Under Serum Concentration-Time Curve Over a Dosing Interval From Time Zero to Tau (AUC-tau) of M6223', 'description': 'Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval.', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycle 1 (Cycle is of 21 days in Q3W regimen)'}`
    • Field `outcomesModule.secondaryOutcomes.[16]` changed from `{'measure': 'Part 1A and 1B: Disease Control According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator', 'timeFrame': 'From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)'}` to `{'measure': 'Part 1A and 1B: Overall Survival', 'description': 'Overall survival was defined as the time (in months) from first study drug administration to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.', 'timeFrame': 'From first study drug administration to the date of death due to any cause (approximately 2 years 11 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[1]` changed from `{'measure': 'Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of M6223', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)'}` to `{'measure': 'Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of M6223', 'description': 'Area under the serum concentration time curve from time zero to infinity, calculated as AUC0 t + AUCextra. AUCextra represents an extrapolated value obtained by Clast/λz, where Clast is the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above LLQ and λz is elimination rate constant.', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)'}`
    • Field `outcomesModule.primaryOutcomes.[3]` changed from `{'measure': 'Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Clinical Laboratory Measures', 'timeFrame': 'Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)'}` to `{'measure': 'Part 1A and 1B: Number of Participants With Clinically Meaningful Change From Baseline in Laboratory Values', 'description': 'Number of participants with clinically meaningful change from baseline in laboratory parameters were reported. Clinically meaningful abnormalities (identified as laboratory values having CTCAE grades \\>= 3). Laboratory investigation included hematology, biochemistry, urinalysis, and coagulation.', 'timeFrame': 'Approximately 2 years 11 months'}`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'M6223', 'description': 'Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.', 'armGroupLabels': ['Part 1A: M6223 Monotherapy']}` to `{'type': 'DRUG', 'name': 'M6223', 'description': 'Participants received an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.', 'armGroupLabels': ['Part 1A: M6223 Monotherapy']}`
    • Field `outcomesModule.secondaryOutcomes.[9]` changed from `{'measure': 'Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Bintrafusp alfa', 'timeFrame': 'Pre-dose up to 14 days (in Q2W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen)'}` to `{'measure': 'Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Bintrafusp Alfa', 'description': 'Ctrough is the concentration prior to study drug administration.', 'timeFrame': 'Day 1 of Treatment of Cycles 1 and 4 from time zero to 14 days postdose'}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Bintrafusp alfa', 'description': 'Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.', 'armGroupLabels': ['Part1B: M6223 + Bintrafusp alfa']}` to `{'type': 'DRUG', 'name': 'Bintrafusp alfa', 'description': 'Participants received an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.', 'armGroupLabels': ['Part1B: M6223 + Bintrafusp alfa']}`
    • Field `outcomesModule.primaryOutcomes.[1]` changed from `{'measure': 'Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) According to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5', 'timeFrame': 'Time from first study drug administration to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)'}` to `{'measure': 'Part 1A and 1B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events that started or worsened after first dose of study intervention until 30 days after last dose. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.', 'timeFrame': 'Approximately 2 years 11 months'}`
    • Field `outcomesModule.secondaryOutcomes.[13]` changed from `{'measure': 'Part 1A and IB: Best Overall Response According to Response C

NCT04374877

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-06` to `2026-07-14`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-10` to `2026-07-15`
    • Field `contactsLocationsModule.overallOfficials.[0]name` changed from `Koho Iizuka, MD` to `Study Director`
    • Field `contactsLocationsModule.overallOfficials.[0]affiliation` changed from `Coherus BioSciences` to `Coherus Oncology`
    • Field `contactsLocationsModule.overallOfficials.[0]role` changed from `STUDY_CHAIR` to `STUDY_DIRECTOR`

NCT06346197

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-16` to `2026-06-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-21` to `2026-06-25`
    • Field `contactsLocationsModule.locations.[1]facility` changed from `Centre Léon Bérard` to `CHU de Clermont-Ferrand`
    • Field `contactsLocationsModule.locations.[1]city` changed from `Lyon` to `Clermont-Ferrand`
    • Field `contactsLocationsModule.locations.[1]zip` changed from `69008` to `63000`
    • Field `contactsLocationsModule.locations.[1]contacts.[0]name` changed from `Clélia COUTZAC, MD` to `Marine JARY, Dr`
    • Field `contactsLocationsModule.locations.[1]contacts.[0]email` changed from `clelia.coutzac@lyon.unicancer.fr` to `mjary@chu-clermontferrand.fr`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lat` changed from `45.74906` to `45.77969`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lon` changed from `4.84789` to `3.08682`
    • Field `contactsLocationsModule.locations.[2]facility` changed from `Hôpital Privé Jean Mermoz` to `Centre Léon Bérard`
    • Field `contactsLocationsModule.locations.[2]contacts.[0]name` changed from `Chloé VERNET, Dr` to `Clélia COUTZAC, MD`
    • Field `contactsLocationsModule.locations.[2]contacts.[0]email` changed from `chloe.vernet2@gmail.com` to `clelia.coutzac@lyon.unicancer.fr`
    • Field `contactsLocationsModule.locations.[3]facility` changed from `Institut Paoli Calmettes` to `Hôpital Privé Jean Mermoz`
    • Field `contactsLocationsModule.locations.[3]city` changed from `Marseille` to `Lyon`
    • Field `contactsLocationsModule.locations.[3]zip` changed from `13000` to `69008`
    • Field `contactsLocationsModule.locations.[3]contacts.[0]name` changed from `Christelle DE LA FOUCHARDIERE, MD` to `Chloé VERNET, Dr`
    • Field `contactsLocationsModule.locations.[3]contacts.[0]phone` changed from `4 91 22 35 03` to `04 37 53 87 26`
    • Field `contactsLocationsModule.locations.[3]contacts.[0]email` changed from `DELAFOUCHARDIEREC@ipc.unicancer.fr` to `chloe.vernet2@gmail.com`
    • Field `contactsLocationsModule.locations.[3]geoPoint.lat` changed from `43.29695` to `45.74906`
    • Field `contactsLocationsModule.locations.[3]geoPoint.lon` changed from `5.38107` to `4.84789`
    • Field `contactsLocationsModule.locations.[4]facility` changed from `Institut Mutualiste Montsouris` to `Institut Paoli Calmettes`
    • Field `contactsLocationsModule.locations.[4]city` changed from `Paris` to `Marseille`
    • Field `contactsLocationsModule.locations.[4]zip` changed from `75000` to `13000`
    • Field `contactsLocationsModule.locations.[4]contacts.[0]name` changed from `Raphaël COLLE, Dr` to `Christelle DE LA FOUCHARDIERE, MD`
    • Field `contactsLocationsModule.locations.[4]contacts.[0]phone` changed from `01 56 61 62 41` to `4 91 22 35 03`
    • Field `contactsLocationsModule.locations.[4]contacts.[0]email` changed from `raphael.colle@imm.fr` to `DELAFOUCHARDIEREC@ipc.unicancer.fr`
    • Field `contactsLocationsModule.locations.[4]geoPoint.lat` changed from `48.85341` to `43.29695`
    • Field `contactsLocationsModule.locations.[4]geoPoint.lon` changed from `2.3488` to `5.38107`
    • Field `contactsLocationsModule.locations.[5]facility` changed from `CHU de Poitiers` to `Institut Mutualiste Montsouris`
    • Field `contactsLocationsModule.locations.[5]city` changed from `Poitiers` to `Paris`
    • Field `contactsLocationsModule.locations.[5]zip` changed from `86000` to `75000`
    • Field `contactsLocationsModule.locations.[5]contacts.[0]name` changed from `David TOUGERON, Pr` to `Raphaël COLLE, Dr`
    • Field `contactsLocationsModule.locations.[5]contacts.[0]phone` changed from `5 49 44 42 93` to `01 56 61 62 41`
    • Field `contactsLocationsModule.locations.[5]contacts.[0]email` changed from `David.TOUGERON@chu-poitiers.fr` to `raphael.colle@imm.fr`
    • Field `contactsLocationsModule.locations.[5]geoPoint.lat` changed from `46.58261` to `48.85341`
    • Field `contactsLocationsModule.locations.[5]geoPoint.lon` changed from `0.34348` to `2.3488`
    • New field added: `root['contactsLocationsModule']['locations'][1]['contacts'][0]['phone']`
    • New field added: `root['contactsLocationsModule']['locations'][1]['contacts'][0]['phoneExt']`
    • Field removed: `root['contactsLocationsModule']['locations'][2]['contacts'][0]['phone']`
    • Field removed: `root['contactsLocationsModule']['locations'][2]['contacts'][0]['phoneExt']`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-02` to `2026-04-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-08` to `2026-04-21`
  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-23` to `2026-04-02`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-25` to `2026-04-08`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Male or female patient ≥18 years of age at time of informed consent form signature.
      • Patient with MSI-H/dMMR, HER2 negativeadvanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.
      • Patient to be treated with a first line therapy for locally advanced/metastatic disease.
      • No prior treatment with chemotherapy for locally advanced/metastatic disease.
    • o Note - adjuvant or neoadjuvant chemotherapy is allowed providing that 6 months have relapsed between completion of adjuvant chemotherapy and recurrence.
      • Measurable disease (outside any previous irradiated field within the past 6 months) defined as at least one unidimensional lesion that can be accurately measured as ≥ 10 mm with CT scan according to RECIST V1.1 (Appendix 01).
      • Note: Lesions intended to be biopsied should not be defined as target lesions.
      • Note: previously irradiated lesions can be selected as target lesion only if recurrence/PD is documented after RT.
      • Patient with PS ECOG 0 or 1 (Appendix 02).
      • Adequate hematologic and end-organ function, defined by the following laboratory test results:
    • Absolute neutrophil count ≥ 1.5 109/L (without growth factor support within 14 d) Platelets ≥ 100 109/L (without transfusion for platelets within 7 d) Hemoglobin ≥ 9 g/dL (without transfusion within 7 d) Creatinine clearance according to CKD-EPI ≥ 30 mL/min/1.73 m2 Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3 x ULN is acceptable) ASAT and ALAT ≤ 3 x ULN (or up to 5 x ULN in case of liver metastasis or hepatic infiltration)
      • Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of the primary or metastatic tumor tissue (resection or biopsy) with an associated pathology report must be available. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells and a tumor surface area ≥ 5mm2 or biopsiable disease (see next inclusion criteria).
      • Tumor lesion visible by medical imaging and accessible to repeatable percutaneous or endoscopic sampling that permits core needle biopsy without unacceptable risk of a significant procedural complications, and suitable for retrieval of a minimum of 4 cores with a needle minimum diameter :16-gauge.
      • Note 1: Fine needle aspirates, bone biopsies do not satisfy the requirement for tumor tissue.
      • Note 2: Tumor lesions used for biopsy should not be lesions used as RECIST 1.1 target lesions unless there are no other lesions suitable for biopsy. If a RECIST target lesion is used for biopsy, the lesion must be ≥ 2 cm in longest diameter.
      • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at the Screening Visit (within 72 hours of first dose of study drugs) and must agree to use highly effective contraceptive measures starting with the Screening Visit through
      • 9 months after the end of the treatment with oxaliplatin
      • 6 months after the end of the treatment with fluorouracil
      • 5 months after the end of the treatment with nivolumab or botensilimab or Balstilimab
      • 6 months for capecitabine
      • Highly effective contraception is defined in Appendix 03.
    • Note Non-childbearing potential is defined as:
      1. ≥ 50 years of age and has not had menses for greater than 1 year.
      1. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
      1. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
      • Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 6 months after the end of the treatment with oxaliplatine or 3 months after the last dose for other study treatments is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
      • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.
      • Patients must be covered by a medical insurance.
    • Exclusion Criteria:
      • Oesogastric cancer eligible to treatment with curative intent
      • Patients previously treated by anti-PD-1, anti-PD-L1, or anti-CTLA-4 or any other immunotherapy
      • Patients with surgery or radiotherapy within less than 4 weeks before C1D1
      • Patients with persistent AE Grade \>1 related to previous anti-cancer treatment, except alopecia (all grades), laboratory value according to criteria I7.
      • Patients with: hypokalemia, hypomagnesemia, hypocalcemia less than normal
      • Patients with known prolongation QT/QTc interval i.e. QT/QTc interval longer than 450 msec for men and longer than 470 msec for women according to the inclusion ECG.
      • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
    • Note: Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:
      • Measurable disease, per RECIST v1.1, must be present outside the CNS.
      • The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.
      • Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).
      • There is no evidence of interim progression between completion of CNS-directed therapy and initiation of study treatment.
      • The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, neurosurgical resection within 21 days prior to initiation of study treatment.
      • The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted. A minimal wash-out period of 10days for corticosteroids is required.
      • Patients with other malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints (basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer), or with no evidence of disease for ≥ 2 years.
      • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
      • of ILD or non-infectious pneumonitis requiring glucocorticoids.
      • History of allogeneic organ transplant.
      • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
      • Patient with peripheral sensory neuropathy with functional impairment.
      • Patients with clinically significant active heart disease or myocardial infarction within 6 months, history of uncontrolled or symptomatic cardiac disease.
      • Patient with recent (within 7d before C1D1) or concomitant treatment with brivudine.
      • Patient with complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥ 150 ng/mL) or partial deficit in DPD (i.e. blood uracil level between ≥ 16 ng/ml and \< 150 ng/mL)
      • Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
      • Patient with Live vaccines injection within 4 weeks before C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
      • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs).
      • History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
      • Patients with documented:
      • Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) unless their HBV is stably controlled on nucleoside analogs (eg entecavir or tenofovir) which will be continued for the duration of the study. Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1.
      • Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA, or
      • HIV infection
      • Prior organ or bone marrow transplant.
      • Pregnant or lactating women.` to `Inclusion Criteria:
      • Male or female patient ≥18 years of age at time of informed consent form signature.
      • Patient with MSI-H/dMMR, HER2 negativeadvanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5. Note :The claudin 18.2 status must be known and documented before inclusion.
      • Patient to be treated with a first line therapy for locally advanced/metastatic disease.
      • No prior treatment with chemotherapy for locally advanced/metastatic disease.
    • o Note - adjuvant or neoadjuvant chemotherapy is allowed providing that 6 months have relapsed between completion of adjuvant chemotherapy and recurrence.
      • Measurable disease (outside any previous irradiated field within the past 6 months) defined as at least one unidimensional lesion that can be accurately measured as ≥ 10 mm with CT scan according to RECIST V1.1 (Appendix 01).
      • Note: Lesions intended to be biopsied should not be defined as target lesions.
      • Note: previously irradiated lesions can be selected as target lesion only if recurrence/PD is documented after RT.
      • Patient with PS ECOG 0 or 1 (Appendix 02).
      • Adequate hematologic and end-organ function, defined by the following laboratory test results:
    • Absolute neutrophil count ≥ 1.5 109/L (without growth factor support within 14 d) Platelets ≥ 100 109/L (without transfusion for platelets within 7 d) Hemoglobin ≥ 9 g/dL (without transfusion within 7 d) Creatinine clearance according to CKD-EPI ≥ 30 mL/min/1.73 m2 Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3 x ULN is acceptable) ASAT and ALAT ≤ 3 x ULN (or up to 5 x ULN in case of liver metastasis or hepatic infiltration)
      • Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of the primary or metastatic tumor tissue (resection or biopsy) with an associated pathology report must be available. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells and a tumor surface area ≥ 5mm2 or biopsiable disease (see next inclusion criteria).
      • Tumor lesion visible by medical imaging and accessible to repeatable percutaneous or endoscopic sampling that permits core needle biopsy without unacceptable risk of a significant procedural complications, and suitable for retrieval of a minimum of 4 cores with a needle minimum diameter :16-gauge.
      • Note 1: Fine needle aspirates, bone biopsies do not satisfy the requirement for tumor tissue.
      • Note 2: Tumor lesions used for biopsy should not be lesions used as RECIST 1.1 target lesions unless there are no other lesions suitable for biopsy. If a RECIST target lesion is used for biopsy, the lesion must be ≥ 2 cm in longest diameter.
      • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at the Screening Visit (within 72 hours of first dose of study drugs) and must agree to use highly effective contraceptive measures starting with the Screening Visit through
      • 9 months after the end of the treatment with oxaliplatin
      • 6 months after the end of the treatment with fluorouracil
      • 5 months after the end of the treatment with nivolumab or botensilimab or Balstilimab
      • 6 months for capecitabine
      • Highly effective contraception is defined in Appendix 03.
    • Note Non-childbearing potential is defined as:
      1. ≥ 50 years of age and has not had menses for greater than 1 year.
      1. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
      1. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
      • Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 6 months after the end of the treatment with oxaliplatine or 3 months after the last dose for other study treatments is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
      • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.
      • Patients must be covered by a medical insurance.
    • Exclusion Criteria:
      • Oesogastric cancer eligible to treatment with curative intent
      • Patients previously treated by anti-PD-1, anti-PD-L1, or anti-CTLA-4 or any other immunotherapy
      • Patients with surgery or radiotherapy within less than 4 weeks before C1D1
      • Patients with persistent AE Grade \>1 related to previous anti-cancer treatment, except alopecia (all grades), laboratory value according to criteria I7.
      • Patients with: hypokalemia, hypomagnesemia, hypocalcemia less than normal
      • Patients with known prolongation QT/QTc interval i.e. QT/QTc interval longer than 450 msec for men and longer than 470 msec for women according to the inclusion ECG.
      • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
    • Note: Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:
      • Measurable disease, per RECIST v1.1, must be present outside the CNS.
      • The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.
      • Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).
      • There is no evidence of interim progression between completion of CNS-directed therapy and initiation of study treatment.
      • The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, neurosurgical resection within 21 days prior to initiation of study treatment.
      • The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted. A minimal wash-out period of 10days for corticosteroids is required.
      • Patients with other malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints (basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer), or with no evidence of disease for ≥ 2 years.
      • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
      • of ILD or non-infectious pneumonitis requiring glucocorticoids.
      • History of allogeneic organ transplant.
      • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
      • Patient with peripheral sensory neuropathy with functional impairment.
      • Patients with clinically significant active heart disease or myocardial infarction within 6 months, history of uncontrolled or symptomatic cardiac disease.
      • Patient with recent (within 7d before C1D1) or concomitant treatment with brivudine.
      • Patient with complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥ 150 ng/mL) or partial deficit in DPD (i.e. blood uracil level between ≥ 16 ng/ml and \< 150 ng/mL)
      • Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
      • Patient with Live vaccines injection within 4 weeks before C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
      • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs).
      • History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
      • Patients with documented:
      • Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) unless their HBV is stably controlled on nucleoside analogs (eg entecavir or tenofovir) which will be continued for the duration of the study. Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1.
      • Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA, or
      • HIV infection
      • Prior organ or bone marrow transplant.
      • Pregnant or lactating women.`
    • Field `contactsLocationsModule.locations.[0]contacts.[0]email` changed from `chloe.verner2@gmail.com` to `chloe.vernet2@gmail.com`
    • New field added: `root['contactsLocationsModule']['locations'][1]['zip']`
    • New field added: `root['contactsLocationsModule']['locations'][2]['zip']`
  • 2026-03-26 02:29:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-27` to `2026-03-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-02` to `2026-03-25`
  • 2026-03-03 00:59:13 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-02-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-26` to `2026-03-02`

NCT05014815

  • 2026-06-24 14:19:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[49]geoPoint.lat` changed from `36.74484` to `36.14168`
    • Field `contactsLocationsModule.locations.[49]geoPoint.lon` changed from `127.13739` to `126.95444`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `contactsLocationsModule.locations.[57]geoPoint.lat` changed from `37.866` to `36.31392`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lon` changed from `127.34942` to `126.69716`

NCT04746924

  • 2026-07-28 00:26:05 (Trial Update)
    • New field added: `root['referencesModule']`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `identificationModule.organization.fullName` changed from `BeiGene` to `BeOne Medicines`
    • Field `statusModule.statusVerifiedDate` changed from `2025-06` to `2026-04`
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `TERMINATED`
    • Field `statusModule.startDateStruct.date` changed from `2021-06-08` to `2021-05-24`
    • Field `statusModule.completionDateStruct.date` changed from `2026-03-31` to `2026-03-18`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-06-23` to `2026-04-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-06-24` to `2026-05-12`
    • Field `descriptionModule.briefSummary` changed from `The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.` to `The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).`
    • Field `designModule.enrollmentInfo.count` changed from `662` to `669`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Key Inclusion Criteria:
      1. Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.
      1. No prior systemic treatment for metastatic NSCLC.
      1. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
      1. Tumors with PD-L1 expressed in ≥ 50% tumor cells.
      1. At least 1 measurable lesion as defined per RECIST v1.1.
      1. ECOG Performance Status ≤ 1.
    • Key Exclusion Criteria:
      1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
      1. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or ch` to `Key Inclusion Criteria:
      1. Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.
      1. No prior systemic treatment for metastatic NSCLC.
      1. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
      1. Tumors with PD-L1 expressed in ≥ 50% tumor cells.
      1. At least 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
      1. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
    • Key Exclusion Criteria:
      1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
      1. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) dom`
    • Field `contactsLocationsModule.locations.[194]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[194]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[194]geoPoint.lon` changed from `121.3187` to `121.29696`
    • Field `ipdSharingStatementModule` changed from `{'ipdSharing': 'YES'}` to `{'ipdSharing': 'YES', 'description': 'BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.\n\nBeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.\n\nQualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to r`
    • Field `outcomesModule.primaryOutcomes.[0]` changed from `{'measure': 'Overall Survival (OS)', 'description': 'OS will be defined as the time from the date of randomization to the date of death due to any cause.', 'timeFrame': 'Up to approximately 58 months'}` to `{'measure': 'Overall Survival (OS) in Arms A and B', 'description': 'OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.', 'timeFrame': 'From randomization until the end of the study. Maximum time on study was 45.0 months'}`
    • Field `armsInterventionsModule.interventions.[1]armGroupLabels.[0]` changed from `Arm A: Tislelizumab plus Ociperlimab` to `Arm A: Ociperlimab plus Tislelizumab`
    • Field `outcomesModule.secondaryOutcomes.[5]` changed from `{'measure': 'HRQoL: European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Questionnaire', 'description': 'HRQoL will be assessed via PRO using the EQ-5D-5L. The EQ-5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and a visual analog scale (VAS). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The VAS records the respondent\'s self-rated health on a 0 to 100 scale, with 100 = "the best health you can imagine" and 0 = "\'the worst health you can imagine". Lower scores in descriptive dimension indicate better HRQoL and higher VAS scores indicates better health state.', 'timeFrame': 'Within 7 days after permanent treatment discontinuation'}` to `{'measure': 'Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator', 'description': 'DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.', 'timeFrame': 'Up to 38.9 months'}`
    • Field `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Arm B: Pembrolizumab plus Placebo', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.', 'interventionNames': ['Drug: Pembrolizumab', 'Drug: Placebo']}` to `{'label': 'Arm B: Pembrolizumab plus Placebo', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants received pembrolizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.', 'interventionNames': ['Drug: Pembrolizumab', 'Drug: Placebo']}`
    • Field `armsInterventionsModule.interventions.[0]armGroupLabels.[0]` changed from `Arm A: Tislelizumab plus Ociperlimab` to `Arm A: Ociperlimab plus Tislelizumab`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Duration Of Response (DOR) As Assessed By Investigators', 'description': 'DOR will be defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first.', 'timeFrame': 'Up to approximately 58 months'}` to `{'measure': 'Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator', 'description': 'ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1. ORR was a pre-specified secondary endpoint for Arms A and B only.\n\nComplete response is defined as disappearance of all target lesions, disappearance of all nontarget lesions and normalization of tumor marker level, and no new lesions.\n\nPartial response is defined as at least a 30% decrease in the sum of diameters of target lesions, no unequivocal progression of non-target lesions, and no new lesions.', 'timeFrame': 'Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 45.0 months'}`
    • Field `outcomesModule.secondaryOutcomes.[7]` changed from `{'measure': 'Number Of Participants Experiencing Adverse Events (AEs)', 'description': 'The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).', 'timeFrame': '90 days (±14) after last dose'}` to `{'measure': 'Change From Baseline in EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) Index Score, Dyspnea, Coughing, Hemoptysis, Pain in Chest, Pain in Arms/Shoulders, and Peripheral Neuropathy Scores in Arms A and B', 'description': 'The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. The symptom index scale was calculated by taking the mean of all symptom scale scores, and ranges from 0 to 100. Lower scores indicate an improvement in symptoms.\n\nThis was a

NCT07098338

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-25` to `2026-06-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-27` to `2026-07-01`
    • Field `contactsLocationsModule.locations.[0]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[33]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[66]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[67]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[68]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[79]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[82]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-28 03:42:12 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-28` to `2026-05-25`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-29` to `2026-05-27`
    • Field `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-03` to `2026-04-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-05` to `2026-04-29`
    • Field `contactsLocationsModule.locations.[2]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[25]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[26]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[33]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[34]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[38]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[52]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[58]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[58]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-02-10 07:03:50 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-09` to `2026-01`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-03-21` to `2029-04-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-09-25` to `2026-02-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-09-30` to `2026-02-05`
    • Field `descriptionModule.detailedDescription` changed from `The master protocol will include 3 sub-studies, each focused on a specific disease population.
      • Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.
      • Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.
      • Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+
    • Each sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).` to `The master protocol will include 3 sub-studies, each focused on a specific disease population.
      • Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.
      • Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.
      • Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+
    • Each sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).`
    • Field `outcomesModule.primaryOutcomes.[1]description` changed from `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1` to `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1`
    • Field `outcomesModule.secondaryOutcomes.[2]description` changed from `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1 as assessed by Investigator.` to `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1.`
    • Field `contactsLocationsModule.locations.[10]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[11]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[12]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[17]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[26]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[33]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[34]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[36]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[37]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[38]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[41]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[44]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[48]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `armsInterventionsModule.armGroups.[0]` changed from `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['DS-1062']}` to `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['DS-1062']}`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['AZD2936']}` to `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['AZD2936']}`
    • Field `armsInterventionsModule.armGroups.[2]` changed from `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}` to `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}`
    • Field `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['Cyramza']}` to `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['Cyramza']}`

NCT06532539

  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2024-06` to `2025-04`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2025-05` to `2026-08`
    • Field `statusModule.completionDateStruct.date` changed from `2026-05` to `2026-09`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2024-07-29` to `2026-04-21`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2024-08-01` to `2026-04-24`

NCT05127824

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-04` to `2026-07`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-12` to `2027-12`
    • Field `statusModule.completionDateStruct.date` changed from `2026-12` to `2027-12`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-04-30` to `2026-07-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-04` to `2026-07-07`
    • Field removed: `root['oversightModule']['isUsExport']`

NCT05329766

  • 2026-07-30 02:27:11 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-30` to `2026-07-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-07-02` to `2026-07-29`
  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-29` to `2026-06-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-02` to `2026-07-02`
  • 2026-06-03 04:13:53 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-28` to `2026-05-29`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-01` to `2026-06-02`
  • 2026-06-02 04:04:22 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-28` to `2026-05-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-29` to `2026-06-01`
  • 2026-05-26 02:38:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-27` to `2026-04-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-30` to `2026-04-29`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'Columbia University', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}` to `{'facility': 'Research Site', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': 'Memorial Sloan Kettering Cancer Center', 'city': 'New York', 'state': 'New York', 'zip': '10021-0005', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}` to `{'facility': 'Research Site', 'city': 'New York', 'state': 'New York', 'zip': '10021-0005', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}`
    • Field `contactsLocationsModule.locations.[30]` changed from `{'facility': 'CHU de Toulouse_Oncopole', 'city': 'Toulouse', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}` to `{'facility': 'Research Site', 'city': 'Rouen', 'country': 'France', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}`
    • Field `contactsLocationsModule.locations.[25]` changed from `{'facility': 'Centre Léon Bérard _ Lyon', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}` to `{'facility': 'Research Site', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}`
    • Field `contactsLocationsModule.locations.[28]` changed from `{'facility': "Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie", 'city': 'Plérin', 'country': 'France', 'geoPoint': {'lat': 48.53451, 'lon': -2.76975}}` to `{'facility': 'Research Site', 'city': 'Plérin', 'country': 'France', 'geoPoint': {'lat': 48.53451, 'lon': -2.76975}}`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'USC/Norris Comprehensive Cancer Center', 'city': 'Los Angeles', 'state': 'California', 'zip': '90033', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}` to `{'facility': 'Research Site', 'city': 'Los Angeles', 'state': 'California', 'zip': '90033', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Yale Cancer Center', 'city': 'Derby', 'state': 'Connecticut', 'zip': '06418', 'country': 'United States', 'geoPoint': {'lat': 41.32065, 'lon': -73.089}}` to `{'facility': 'Research Site', 'city': 'Derby', 'state': 'Connecticut', 'zip': '06418', 'country': 'United States', 'geoPoint': {'lat': 41.32065, 'lon': -73.089}}`
    • Field `contactsLocationsModule.locations.[36]` changed from `{'facility': 'Clinical Center Kragujevac', 'city': 'Kragujevac', 'country': 'Serbia', 'geoPoint': {'lat': 44.01667, 'lon': 20.91667}}` to `{'facility': 'Research Site', 'city': 'Busan', 'country': 'South Korea', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': 'OU - Stephenson Cancer Center', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73104', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}` to `{'facility': 'Research Site', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73104', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Massachusetts General Hospital', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02109', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}` to `{'facility': 'Research Site', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02109', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}`
    • Field `contactsLocationsModule.locations.[31]` changed from `{'facility': 'Gustave Roussy - Villejuif', 'city': 'Villejuif', 'country': 'France', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}` to `{'facility': 'Research Site', 'city': 'Toulouse', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}`
    • Field `contactsLocationsModule.locations.[40]` changed from `{'facility': 'CHA Bundang Medical Center', 'city': 'Seongnam-si', 'country': 'South Korea', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Ronald Reagan UCLA Medical Center', 'city': 'Santa Monica', 'state': 'California', 'zip': '90024', 'country': 'United States', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}` to `{'facility': 'Research Site', 'city': 'Santa Monica', 'state': 'California', 'zip': '90024', 'country': 'United States', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}`
    • Field `contactsLocationsModule.locations.[34]` changed from `{'facility': 'University Hospital Medical Center (KBC) Bezanijska Kosa', 'city': 'Belgrade', 'country': 'Serbia', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}` to `{'facility': 'Research Site', 'city': 'Kamenitz', 'country': 'Serbia', 'geoPoint': {'lat': 45.22334, 'lon': 19.84263}}`
    • Field `contactsLocationsModule.locations.[16]` changed from `{'facility': 'UHN - Princess Margaret Cancer Centre', 'city': 'Toronto', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}` to `{'facility': 'Research Site', 'city': 'Toronto', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}`
    • Field `contactsLocationsModule.locations.[17]` changed from `{'facility': 'Clínica San Carlos de Apoquindo', 'city': 'Las Condes', 'country': 'Chile', 'geoPoint': {'lat': -33.41636, 'lon': -70.56413}}` to `{'facility': 'Research Site', 'city': 'Las Condes', 'country': 'Chile', 'geoPoint': {'lat': -33.41636, 'lon': -70.56413}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'Duke University', 'city': 'Durham', 'state': 'North Carolina', 'zip': '27710', 'country': 'United States', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}` to `{'facility': 'Research Site', 'city': 'Durham', 'state': 'North Carolina', 'zip': '27710', 'country': 'United States', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}`
    • Field `contactsLocationsModule.locations.[26]` changed from `{'facility': 'Hôpital Timone - Marseille', 'city': 'Marseille', 'country': 'France', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}` to `{'facility': 'Research Site', 'city': 'Marseille', 'country': 'France', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}`
    • Field `contactsLocationsModule.locations.[37]` changed from `{'facility': 'Dong-A University Hospital', 'city': 'Busan', 'country': 'South Korea', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}` to `{'facility': 'Research Site', 'city': 'Daegu', 'country': 'South Korea', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}`
    • Field `contactsLocationsModule.locations.[19]` changed from `{'facility': 'Centro de Estudios Clínicos SAGA', 'city': 'Santiago', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}` to `{'facility': 'Research Site', 'city': 'Santiago', 'country': 'Chile', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'Mayo Clinic - Jacksonville', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}` to `{'facility': 'Research Site', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Vanderbilt-Ingram Cancer Center', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37232', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}` to `{'facility': 'Research Site', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37232', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}`
    • Field `contactsLocationsModule.locations.[33]` changed from `{'facility': 'University Clinical Center of Serbia', 'city': 'Belgrade', 'country': 'Serbia', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}` to `{'facility': 'Research Site', 'city': 'Belgrade', 'country': 'Serbia', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}`
    • Field `contactsLocationsModule.locations.[38]` changed from `{'facility': 'Kyungpook National University Chilgok Hospital', 'city': 'Daegu', 'country': 'South Korea', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}` to `{'facility': 'Research Site', 'city': 'Hwasun', 'country': 'South Korea', 'geoPoint': {'lat': 35.06125, 'lon': 126.98746}}`
    • Field `contactsLocationsModule.locations.[23]` changed from `{'facility': 'Centre Baclesse - CAEN', 'city': 'Caen', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}` to `{'facility': 'Research Site', 'city': 'Caen', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Florida Cancer Specialist - South', 'city': 'Fort Myers', 'state': 'Florida', 'zip': '33901', 'country': 'United States', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}` to `{'facility': 'Research Site', 'city': 'Fort Myers', 'state': 'Florida', 'zip': '33901', 'country': 'United States', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Virginia Cancer Specialists', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}` to `{'facility': 'Research Site', 'city':

NCT07221253

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-17` to `2026-07-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-18` to `2026-07-20`
    • Field `contactsLocationsModule.locations.[0]zip` changed from `35233` to `35205`
    • Field `contactsLocationsModule.locations.[1]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[12]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[12]city` changed from `Jacksonville` to `Gainesville`
    • Field `contactsLocationsModule.locations.[12]zip` changed from `32209` to `32610`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lat` changed from `30.33218` to `29.65163`
    • Field `contactsLocationsModule.locations.[12]geoPoint.lon` changed from `-81.65565` to `-82.32483`
    • Field `contactsLocationsModule.locations.[13]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[18]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[22]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[29]city` changed from `Philadelphia` to `Lancaster`
    • Field `contactsLocationsModule.locations.[29]zip` changed from `19104` to `17601`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lat` changed from `39.95238` to `40.03788`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lon` changed from `-75.16362` to `-76.30551`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[87]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[88]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[89]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[91]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[92]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[96]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[104]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[109]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[129]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[130]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]zip` changed from `30-688` to `31-501`
    • Field `contactsLocationsModule.locations.[133]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[147]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[163]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[164]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[165]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[166]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[167]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-06-19 04:23:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-06`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2029-07-04` to `2029-07-31`
    • Field `statusModule.completionDateStruct.date` changed from `2029-07-04` to `2029-07-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-16` to `2026-06-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-17` to `2026-06-18`
    • Field `contactsLocationsModule.locations.[2]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[17]zip` changed from `40207` to `40217`
    • Field `contactsLocationsModule.locations.[18]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[18]zip` changed from `21205` to `21231`
    • Field `contactsLocationsModule.locations.[31]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[6]city` changed from `Stanford` to `Houston`
    • Field `contactsLocationsModule.locations.[6]state` changed from `California` to `Texas`
    • Field `contactsLocationsModule.locations.[6]zip` changed from `94305-5847` to `77030`
    • Field `contactsLocationsModule.locations.[6]geoPoint.lat` changed from `37.42411` to `29.76328`
    • Field `contactsLocationsModule.locations.[6]geoPoint.lon` changed from `-122.16608` to `-95.36327`
    • Field `contactsLocationsModule.locations.[35]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[37]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[38]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[44]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[56]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[59]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[60]status` changed from `SUSPENDED` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[61]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[63]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[64]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[67]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[68]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[69]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[70]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[71]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[72]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[73]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[74]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[75]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[76]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[77]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[78]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[79]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[104]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[105]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[106]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[107]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[109]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[110]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[113]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[115]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[120]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[121]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[122]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[126]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[134]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[138]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[140]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[142]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[151]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[153]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[155]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[164]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `26.82656` to `40.28464`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `114.95747` to `120.48412`
    • Field `contactsLocationsModule.locations.[84]geoPoint.lat` changed from `51.22172` to `51.22319`
    • Field `contactsLocationsModule.locations.[84]geoPoint.lon` changed from `6.77616` to `6.77927`
    • Field `contactsLocationsModule.locations.[150]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[150]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[150]geoPoint.lon` changed from `121.3187` to `121.29696`
    • Field `contactsLocationsModule.locations.[156]geoPoint.lat` changed from `14.12117` to `14.11985`
    • Field `contactsLocationsModule.locations.[156]geoPoint.lon` changed from `101.00364` to `101.00148`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-09` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-10` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[45]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[61]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[64]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[66]zip` changed from `471003` to `471023`
    • Field `contactsLocationsModule.locations.[108]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[109]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[113]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[114]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[115]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[116]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[126]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[129]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[144]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[151]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-12 14:01:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-07` to `2026-02-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-08` to `2026-02-10`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[39]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[89]city` changed from `Lichtenberg` to `Berlin`
    • Field `contactsLocationsModule.locations.[89]geoPoint.lat` changed from `52.51395` to `52.52437`
    • Field `contactsLocationsModule.locations.[89]geoPoint.lon` changed from `13.49975` to `13.41053`
    • Field `contactsLocationsModule.locations.[103]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[138]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[145]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[147]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05676931

  • 2026-06-02 04:04:22 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-09` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-09-29` to `2026-05-28`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-02` to `2026-06-01`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[24]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lon` changed from `11.88586` to `11.14261`

NCT06790706

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-10` to `2026-06`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-01` to `2026-06-22`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-06` to `2026-06-25`
    • Field `descriptionModule.briefSummary` changed from `Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases. After the standard first-line treatment, there are no other validated treatments for most of them. The management of these patients in ≥ 2nd line treatment relies on historic poorly effective regimens.
    • This creates an inequity between patients with frequent cancers beneficiating from medical progresses and approvals of innovative drugs, and patients with rare cancers are still treated with old and toxic drugs.
    • Few available data on case reports and early phase studies indicate a beneficial role of the immunotherapy in rare cancers.
    • The investigators assume that the combination of Domvanalimab and Zimberelimab is more effective than historical standard treatments in patients with 5 types of advanced rare cancers, after failure of at least one line of standard treatment i` to `Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases. After the standard first-line treatment, there are no other validated treatments for most of them. The management of these patients in ≥ 2nd line treatment relies on historic poorly effective regimens.
    • This creates an inequity between patients with frequent cancers beneficiating from medical progresses and approvals of innovative drugs, and patients with rare cancers are still treated with old and toxic drugs.
    • Few available data on case reports and early phase studies indicate a beneficial role of the immunotherapy in rare cancers.
    • The investigators assume that the combination of Domvanalimab and Zimberelimab is more effective than historical standard treatments in patients with 5 types of advanced rare cancers, after failure of at least one line of standard treatment i`
    • Field `conditionsModule.keywords.[4]` changed from `Thymomas and Thymic Carcinomas` to `Thymic Carcinomas`
    • Field `designModule.enrollmentInfo.count` changed from `154` to `27`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `armsInterventionsModule.armGroups.[2]label` changed from `Cohort 3: B3 thymomas and thymic carcinomas` to `Cohort 3: Thymic carcinomas`
    • Field `armsInterventionsModule.interventions.[0]armGroupLabels.[2]` changed from `Cohort 3: B3 thymomas and thymic carcinomas` to `Cohort 3: Thymic carcinomas`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
    • General inclusion criteria for all cohorts
      • Histologically proven advanced solid tumors that progressed/resisted after minimum one line of standard systemic treatment, or resisted during the first-line of treatment
      • No indication of curative surgery for this disease at inclusion (For cohort 1 only (peritoneal mesothelioma), debulking surgery could be considered after minimum 6 months of study treatment in the case of important tumor response)
      • Evaluable lesions (target or non-target lesions) for radiological response according to RECIST 1.1 (cohorts 3, 4, 5), or mRECIST (cohort 1), or assessable for biological response with serum hCG (cohort 2)
      • Patients older than 18 years
      • Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
      • Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy in absence of medical contraindication (If either a fresh biopsy or archival material ` to `Inclusion Criteria:
    • General inclusion criteria for all cohorts
      • Histologically proven advanced solid tumors that progressed/resisted after minimum one line of standard systemic treatment, or resisted during the first-line of treatment
      • Participation in IMMUNORARE5 trial testing DOMVANALIMAB and ZIMBERELIMAB, validated by a multidisciplinary tumor board recognized by the national reference center, or validated by at least one national coordinator of the cohort
      • No indication of curative surgery for this disease at inclusion (For cohort 1 only (peritoneal mesothelioma), debulking surgery could be considered after minimum 6 months of study treatment in the case of important tumor response)
      • Evaluable lesions (target or non-target lesions) for radiological response according to RECIST 1.1 (cohorts 3, 4, 5), or mRECIST (cohort 1), or assessable for biological response with serum hCG (cohort 2)
      • Patients older than 18 years
      • Patients with Eastern Cooperative Oncology Group (ECOG) per`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][1]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][1]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][2]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][2]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][3]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][3]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][4]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][4]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][5]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][5]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][6]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][6]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][7]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][7]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][8]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][8]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][9]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][9]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][10]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][10]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][11]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][11]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][12]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][12]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][13]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][13]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][14]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][14]['contacts']`

NCT04543617

  • 2026-07-28 00:26:06 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-16` to `2026-07-22`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-17` to `2026-07-23`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-16` to `2026-04-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-20` to `2026-04-17`
    • Field `contactsLocationsModule.locations.[164]facility` changed from `New Cross Hospital` to `Goztepe Prof.Dr. Suleyman Yalcin City Hospital`
    • Field `contactsLocationsModule.locations.[164]city` changed from `Wolverhampton` to `Kadiköy`
    • Field `contactsLocationsModule.locations.[164]zip` changed from `WV10 0QP` to `34722`
    • Field `contactsLocationsModule.locations.[164]country` changed from `United Kingdom` to `Turkey (Türkiye)`
    • Field `contactsLocationsModule.locations.[164]geoPoint.lat` changed from `52.58547` to `41.06639`
    • Field `contactsLocationsModule.locations.[164]geoPoint.lon` changed from `-2.12296` to `41.01294`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[79]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[76]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[76]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[76]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04305041

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[30]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[29]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06996782

  • 2026-07-28 00:26:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-16` to `2026-07-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-17` to `2026-07-21`
    • Field `contactsLocationsModule.locations.[25]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[26]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[99]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-06-24 14:19:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[101]geoPoint.lat` changed from `37.05738` to `41.0225`
    • Field `contactsLocationsModule.locations.[101]geoPoint.lon` changed from `34.58903` to `28.94083`
  • 2026-06-18 04:04:37 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-30` to `2026-06-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-01` to `2026-06-17`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[39]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-27` to `2026-04-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-30` to `2026-05-01`
    • Field `contactsLocationsModule.locations.[77]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[78]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[103]geoPoint.lat` changed from `39.94548` to `37.05738`
    • Field `contactsLocationsModule.locations.[103]geoPoint.lon` changed from `32.87302` to `34.58903`
  • 2026-03-31 02:31:37 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-23` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-24` to `2026-03-30`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[56]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[60]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[62]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[82]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[97]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05665595

  • 2026-05-26 02:38:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[51]state` changed from `Vienna` to `State of Vienna`
    • Field `contactsLocationsModule.locations.[73]state` changed from `Región de Valparaíso` to `Valparaiso`
    • Field `contactsLocationsModule.locations.[99]city` changed from `Ibagué` to `Ibague`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[142]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[142]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[142]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `referencesModule.references.[0]citation` changed from `Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026 Feb 13:S1470-2045(25)00709-0. doi: 10.1016/S1470-2045(25)00709-0. Online ahead of print.` to `Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026 Mar;27(3):327-339. doi: 10.1016/S1470-2045(25)00709-0. Epub 2026 Feb 13.`
  • 2026-02-19 01:00:02 (Trial Update)
    • Minor formatting updates.

NCT06868277

  • 2026-05-26 02:38:42 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-27` to `2026-05-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-02` to `2026-05-14`
    • Field `contactsLocationsModule.locations.[0]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[35]city` changed from `Rosario` to `Renton`
    • Field `contactsLocationsModule.locations.[35]zip` changed from `S2000CVB` to `98055`
    • Field `contactsLocationsModule.locations.[35]country` changed from `Argentina` to `United States`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lat` changed from `-32.94682` to `47.48288`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lon` changed from `-60.63932` to `-122.21707`
    • Field `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[36]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[45]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[47]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[48]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[52]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]city` changed from `São Paulo` to `Santo André`
    • Field `contactsLocationsModule.locations.[57]zip` changed from `03102-006` to `09060-650`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lat` changed from `-23.5475` to `-23.66389`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lon` changed from `-46.63611` to `-46.53833`
    • Field `contactsLocationsModule.locations.[56]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[66]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[70]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[76]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[100]city` changed from `Liuchow` to `Liuzhou`
    • Field `contactsLocationsModule.locations.[126]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[128]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[129]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[132]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[133]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[134]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[135]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[136]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[142]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[146]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[150]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[152]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[155]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[157]city` changed from `Mainz` to `Remscheid`
    • Field `contactsLocationsModule.locations.[157]zip` changed from `55131` to `42859`
    • Field `contactsLocationsModule.locations.[157]geoPoint.lat` changed from `49.98185` to `51.17983`
    • Field `contactsLocationsModule.locations.[157]geoPoint.lon` changed from `8.28008` to `7.1925`
    • Field `contactsLocationsModule.locations.[165]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[168]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[169]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[171]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[179]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[186]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[192]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[193]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[194]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[195]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[197]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[198]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[199]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[200]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[201]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[202]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[203]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[236]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[237]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[257]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[283]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[285]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[286]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[287]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][35]['state']`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[197]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[197]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[197]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-03 00:59:14 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-12` to `2026-02-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-13` to `2026-03-02`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[31]zip` changed from `2000` to `S2000CVB`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[52]city` changed from `Santo André` to `São Paulo`
    • Field `contactsLocationsModule.locations.[52]zip` changed from `09060-650` to `03102-006`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lat` changed from `-23.66389` to `-23.5475`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lon` changed from `-46.53833` to `-46.63611`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[69]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[122]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[148]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[153]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[155]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[157]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[160]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[165]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[224]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[272]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[273]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT06692738

  • 2026-07-28 00:26:06 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)` to `A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)`
    • Field `identificationModule.officialTitle` changed from `A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)` to `A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)`
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2029-02-05` to `2030-07-01`
    • Field `statusModule.completionDateStruct.date` changed from `2029-10-08` to `2030-07-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-09` to `2026-07-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-10` to `2026-07-14`
    • Field `descriptionModule.briefSummary` changed from `The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).` to `The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).`
    • Field `descriptionModule.detailedDescription` changed from `This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).` to `This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous locally advanced or metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).`
    • Field `designModule.enrollmentInfo.count` changed from `880` to `1160`
    • Field `outcomesModule.primaryOutcomes.[0]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.primaryOutcomes.[1]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[0]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[1]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[2]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[3]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[4]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[5]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[6]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[7]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[8]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[9]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Histologically or cytologically documented squamous NSCLC.
      • Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
      • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any actionable driver oncogenes for which there are locally approved targeted 1L therapies.
      • Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%.
      • At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.
      • Adequate organ and bone marrow function.
    • Exclusion Criteria:
      • Presence of small cell and neuroendocrine histology components.
      • Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvuls` to `Inclusion Criteria:
      • Histologically or cytologically documented squamous NSCLC.
      • Stage III B/C or IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
      • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any actionable driver oncogenes for which there are locally approved and available targeted 1L therapies.
      • Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%.
      • At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.
      • Adequate organ and bone marrow function.
    • Exclusion Criteria:
      • Presence of small cell and neuroendocrine histology components.
      • Brain metastases unless asymptomatic, stable, and not requirin`
    • Field `contactsLocationsModule.locations.[36]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[40]status` changed from `RECRUITING` to `NOT_YET_RECRUITING`
    • Field `contactsLocationsModule.locations.[40]city` changed from `Duluth` to `Saginaw`
    • Field `contactsLocationsModule.locations.[40]state` changed from `Minnesota` to `Michigan`
    • Field `contactsLocationsModule.locations.[40]zip` changed from `55802` to `48602`
    • Field `contactsLocationsModule.locations.[40]geoPoint.lat` changed from `46.78327` to `43.41947`
    • Field `contactsLocationsModule.locations.[40]geoPoint.lon` changed from `-92.10658` to `-83.95081`
    • Field `contactsLocationsModule.locations.[41]city` changed from `Rochester` to `Duluth`
    • Field `contactsLocationsModule.locations.[41]zip` changed from `55905` to `55802`
    • Field `contactsLocationsModule.locations.[41]geoPoint.lat` changed from `44.02163` to `46.78327`
    • Field `contactsLocationsModule.locations.[41]geoPoint.lon` changed from `-92.4699` to `-92.10658`
    • Field `contactsLocationsModule.locations.[42]city` changed from `Bridgeton` to `Rochester`
    • Field `contactsLocationsModule.locations.[42]state` changed from `Missouri` to `Minnesota`
    • Field `contactsLocationsModule.locations.[42]zip` changed from `63044` to `55905`
    • Field `contactsLocationsModule.locations.[42]geoPoint.lat` changed from `38.767` to `44.02163`
    • Field `contactsLocationsModule.locations.[42]geoPoint.lon` changed from `-90.41151` to `-92.4699`
    • Field `contactsLocationsModule.locations.[43]status` changed from `WITHDRAWN` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]city` changed from `Columbia` to `Bridgeton`
    • Field `contactsLocationsModule.locations.[43]zip` changed from `65212` to `63044`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lat` changed from `38.95171` to `38.767`
    • Field `contactsLocationsModule.locations.[43]geoPoint.lon` changed from `-92.33407` to `-90.41151`
    • Field `contactsLocationsModule.locations.[44]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[44]city` changed from `Kansas City` to `Columbia`
    • Field `contactsLocationsModule.locations.[44]zip` changed from `64108` to `65212`
    • Field `contactsLocationsModule.locations.[44]geoPoint.lat` changed from `39.09973` to `38.95171`
    • Field `contactsLocationsModule.locations.[44]geoPoint.lon` changed from `-94.57857` to `-92.33407`
    • Field `contactsLocationsModule.locations.[45]city` changed from `Lincoln` to `Kansas City`
    • Field `contactsLocationsModule.locations.[45]state` changed from `Nebraska` to `Missouri`
    • Field `contactsLocationsModule.locations.[45]zip` changed from `68506` to `64108`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lat` changed from `40.8` to `39.09973`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lon` changed from `-96.66696` to `-94.57857`
    • Field `contactsLocationsModule.locations.[46]city` changed from `Camden` to `Lincoln`
    • Field `contactsLocationsModule.locations.[46]state` changed from `New Jersey` to `Nebraska`
    • Field `contactsLocationsModule.locations.[46]zip` changed from `08103` to `68506`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lat` changed from `39.92595` to `40.8`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lon` changed from `-75.11962` to `-96.6
  • 2026-06-11 04:04:08 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-30` to `2026-06-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-01` to `2026-06-10`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[50]city` changed from `Canton` to `Fort Wayne`
    • Field `contactsLocationsModule.locations.[50]state` changed from `Ohio` to `Indiana`
    • Field `contactsLocationsModule.locations.[50]zip` changed from `44718` to `46845`
    • Field `contactsLocationsModule.locations.[50]geoPoint.lat` changed from `40.79895` to `41.1306`
    • Field `contactsLocationsModule.locations.[50]geoPoint.lon` changed from `-81.37845` to `-85.12886`
    • Field `contactsLocationsModule.locations.[34]city` changed from `South Portland` to `Scarborough`
    • Field `contactsLocationsModule.locations.[34]zip` changed from `04106` to `04074`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lat` changed from `43.64147` to `43.57814`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lon` changed from `-70.24088` to `-70.32172`
    • Field `contactsLocationsModule.locations.[111]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[142]status` changed from `SUSPENDED` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[180]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[220]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-30` to `2026-04-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-31` to `2026-05-01`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[130]geoPoint.lat` changed from `22.8836` to `30.17415`
    • Field `contactsLocationsModule.locations.[130]geoPoint.lon` changed from `107.264` to `120.97629`
    • Field `contactsLocationsModule.locations.[276]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[276]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[276]geoPoint.lon` changed from `121.3187` to `121.29696`
    • Field `contactsLocationsModule.locations.[279]geoPoint.lat` changed from `13.7775` to `13.77706`
    • Field `contactsLocationsModule.locations.[279]geoPoint.lon` changed from `100.51977` to `100.51958`
    • Field `contactsLocationsModule.locations.[282]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[283]zip` changed from `07058` to `07059`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[202]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[202]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[202]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-24` to `2026-03-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-25` to `2026-03-31`
    • Field `contactsLocationsModule.locations.[0]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[156]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[227]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[251]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][274]['zip']`

NCT04256421

  • 2026-05-26 02:38:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[109]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[109]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[109]geoPoint.lon` changed from `121.3187` to `121.29696`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-09` to `2026-03-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-28` to `2026-04-03`
    • Field `outcomesModule.primaryOutcomes.[0]measure` changed from `Investigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PAS)` to `Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)`
    • Field `outcomesModule.primaryOutcomes.[0]description` changed from `PFS was defined as the time from randomization to the first documented disease progression (PD) as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurred first. PD: at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \>/= 5 millimeters (mm).` to `PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm).`
    • Field `outcomesModule.primaryOutcomes.[0]timeFrame` changed from `From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)` to `From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)`
    • Field `contactsLocationsModule.locations.[57]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lon` changed from `11.88586` to `11.77208`
    • Field `outcomesModule.secondaryOutcomes.[13]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 GHS/QoL in the FAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported global health status (GHS)/ quality of life (QoL). TTCD was determined based on patient-reported GHS/QoL (items 29-30) as collected and measured by the EORTC QLQ-C30. HS/ QoL items are scored on a 7-point scale that ranges from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health related quality of life. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 GHS/QoL in the FAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[0]` changed from `{'measure': 'PFS in the FAS', 'description': 'PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'PFS in the FAS', 'description': 'PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[6]` changed from `{'measure': 'Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 6, Month 12'}` to `{'measure': 'Investigator-assessed PFS Rates at 6 Months and 12 Months in the PAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the Kaplan-Meier (K-M) method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 6, Month 12'}`
    • Field `outcomesModule.secondaryOutcomes.[16]` changed from `{'measure': 'Cmin of Atezolizumab', 'timeFrame': 'At the end of each cycle (each cycle is 21 days) of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months)'}` to `{'measure': 'Minimum Serum Concentration (Cmin) of Tiragolumab', 'timeFrame': 'At the end of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[10]` changed from `{'measure': 'Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Physical Functioning in the PAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in physical functioning. TTCD was determined based on patient-reported physical functioning (items 1-5) as collected and measured by the EORTC QLQ-C30. The PF is measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the physical function subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in physical functioning subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 (QLQ-C30) Physical Functioning (PF) in the PAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[15]` changed from `{'measure': 'Minimum Serum Concentration (Cmin) of Tiragolumab', 'timeFrame': 'At the end of each cycle (each cycle is 21 days) of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months)'}` to `{'measure': 'Number of Participants With Severity of Cytokine-release Syndrome (CRS), as Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale', 'description': 'CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades: Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \\& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS. Only non zero values have been reported.', 'timeFrame': 'Up to 58 months'}`
    • Field `outcomesModule.secondaryOutcomes.[17]` changed from `{'measure': 'Maximum Serum Concentration (Cmax) of Tiragolumab', 'timeFrame': 'Predose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (each cycle is 21 days)'}` to `{'measure': 'Cmin of Atezolizumab', 'timeFrame': 'At the end of each Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[19]` changed from `{'measure': 'Number of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab', 'description': 'Reported here is the number of participants who had a positive ADA assay result at baseline and the number of participants positive for treatment emergent ADAs. The participants positive for treatment emergent ADAs include treatment-induced and treatment-enhanced ADA positive participants. Treatment-induced ADAs are participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that were at least 0.60 t.u. greater than the baseline titer result. The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Predose on Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4, 8,12 and 16 and at treatment discontinuation (TD) visit (up to 24 months)'}` to `{'measure': 'Cmax of Atezolizumab', 'timeFrame': 'Pre-dose and 30 minutes post EOI on Day 1 of Cycle 1 (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[14]` changed from `{'measure': 'Percentage of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'Up to 65 months'}` to `{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study were also considered as AEs.', 'timeFrame': 'Up to 58 months'}`
    • Field `outcomesModule.secondaryOutcomes.[8]` changed from `{'measure': 'Overall Survival Rates at 12 Months and 24 Months in the PAS', 'description': 'Overall survival rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 12, Month 24'}` to `{'measure': 'OS Rates at 12 Months and 24 Months in the PAS', 'description': 'OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 12, Month 24'}`
    • Field `outcomesModule.secondaryOutcomes.[18]` changed from `{'measure': 'Cmax of Atezolizumab', 'timeFrame': 'Predose and 30 minutes post EOI on Day 1 of Cycle 1 (each cycle is 21 days)'}` to `{'measure': 'Maximum Serum Concentration (Cmax) of Tiragolumab', 'timeFrame': 'Pre-dose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[21]` changed from `{'measure': 'Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index-based and Visual Analog Scale Scores', 'description': "The EQ-5D-5L is a validated self-report health status questionnaire that was used to calculate a health status utility score for use in health economic analyses. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a visual analog scale (VAS) that measured health state. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100 A single composite score was calculated based on the responses as an indicator of the participant's health status. The scale ranges 0-100, 0=worst health and 100=best health.", 'timeFrame': 'From baseline up to 65 months'}` to `{'measure': 'Number of Participants With ADAs to Atezolizumab', 'description': 'Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at TD visit (up to 24 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[5]` changed from `{'measure': 'Investigator-Assessed DOR in the FAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR: was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD= at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'Investigator-assessed DOR in the FAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[3]` changed from `{'measure': 'Investigator-Assessed Confirmed ORR in the FAS', 'description': 'ORR was defined as the percentage of participants with CR or PR as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.', 'timeFrame': 'From randomization up to approximately 24 months'}` to `{'measure': 'Investigator-assessed Confirmed ORR in the FAS', 'description': 'ORR was defined as the percentage of participants with CR or PR as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.', 'timeFrame': 'From randomization up to approximately 24 months'}`
    • Field `outcomesModule.secondaryOutcomes.[11]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 Physical Functioning in the FAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in physical functioning. TTCD was determined based on patient-reported physical functioning (items 1-5) as collected and measured by the EORTC QLQ-C30. The PF is measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the physical function subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in physical functioning subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 Physical Functioning in the FAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[20]` changed from `{'measure': 'Number of Participants With ADAs to Atezolizumab', 'description': 'Reported here is the number of participants who had a positive ADA assay result at baseline and the number of participants positive for treatment emergent ADAs. The number of participants positive for treatment emergent ADAs includes treatment-induced and treatment-enhanced ADA positive participants. Treatment-induced ADAs are participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that were at least 0.60 t.u. greater than the baseline titer result. The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Predose on Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4, 8,12 and 16 and at TD visit (up to 24 months)'}` to `{'measure': 'Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab', 'description': 'Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at treatment discontinuation (TD) visit (up to 24 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[7]` changed from `{'measure': 'Investigator-Assessed PFS Rates at 6 Months and 12 Months in the FAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 6, Month 12'}` to `{'measure': 'Investigator-assessed PFS Rates at 6 Months and 12 Months in the FAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 6, Month 12'}`
    • Field `outcomesModule.secondaryOutcomes.[9]` changed from `{'measure': 'Overall Survival Rates at 12 Months and 24 Months in the FAS', 'description': 'Overall survival rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 12, Month 24'}` to `{'measure': 'OS Rates at 12 Months and 24 Months in the FAS', 'description': 'OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 12, Month 24'}`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PAS', 'description': 'ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.', 'timeFrame': 'From randomization up to approximately 24 months'}` to `{'measure': 'Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS', 'description': 'ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.', 'timeFrame': 'From randomization up to approximately 24 months'}`
    • Field `outcomesModule.secondaryOutcomes.[4]` changed from `{'measure': 'Investigator-Assessed Duration of Response (DOR) in the PAS', 'description': 'DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR: was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD= at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'Investigator-assessed Duration of Response (DOR) in the PAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response (OR) to PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[12]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality of Life (QoL) in the PAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported global health status (GHS)/ quality of life (QoL). TTCD was determined based on patient-reported GHS/QoL (items 29-30) as collected and measured by the EORTC QLQ-C30. HS/QoL items are scored on a 7-point scale that ranges from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health related quality of life. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality-of-life (QoL) in the PAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • New field added: `root['outcomesModule']['otherOutcomes']`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[52]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06989112

  • 2026-06-24 14:19:42 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-05` to `2026-06-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-06` to `2026-06-23`
    • Field `contactsLocationsModule.locations.[22]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[27]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[41]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[132]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[134]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[135]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[137]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[150]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[154]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[172]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[174]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[183]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[190]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[211]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[236]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-07` to `2026-05-05`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-08` to `2026-05-06`
    • Field `sponsorCollaboratorsModule.collaborators.[1]name` changed from `Gynecologic Oncology Group (GOG) Foundation Inc.` to `European Network of Gynaecological Oncological Trial Groups (ENGOT)`
    • Field `sponsorCollaboratorsModule.collaborators.[1]class` changed from `UNKNOWN` to `OTHER`
    • Field `contactsLocationsModule.locations.[1]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]city` changed from `Saint Johnsbury` to `Lebanon`
    • Field `contactsLocationsModule.locations.[55]state` changed from `Vermont` to `New Hampshire`
    • Field `contactsLocationsModule.locations.[55]zip` changed from `05819` to `03756`
    • Field `contactsLocationsModule.locations.[55]geoPoint.lat` changed from `44.41922` to `43.64229`
    • Field `contactsLocationsModule.locations.[55]geoPoint.lon` changed from `-72.01509` to `-72.25176`
    • Field `contactsLocationsModule.locations.[27]city` changed from `Jackson` to `Winston-Salem`
    • Field `contactsLocationsModule.locations.[27]state` changed from `Mississippi` to `North Carolina`
    • Field `contactsLocationsModule.locations.[27]zip` changed from `39216` to `27157`
    • Field `contactsLocationsModule.locations.[27]geoPoint.lat` changed from `32.29876` to `36.09986`
    • Field `contactsLocationsModule.locations.[27]geoPoint.lon` changed from `-90.18481` to `-80.24422`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[59]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[73]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[91]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[117]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[136]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[138]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[177]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-11` to `2026-04-07`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-12` to `2026-04-08`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[70]city` changed from `Ghent` to `Oklahoma City`
    • Field `contactsLocationsModule.locations.[70]zip` changed from `9000` to `73104`
    • Field `contactsLocationsModule.locations.[70]country` changed from `Belgium` to `United States`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `51.05` to `35.46756`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `3.71667` to `-97.51643`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[88]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[149]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[167]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[208]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[229]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][70]['state']`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[173]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[173]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[173]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-13 02:09:20 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-09` to `2026-03-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-10` to `2026-03-12`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[18]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[45]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[67]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[73]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[81]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[103]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[144]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[146]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[160]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[168]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[172]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[177]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[208]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[220]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[227]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[229]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[230]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[232]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[233]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[243]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[244]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT06627647

  • 2026-07-28 00:26:06 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC` to `A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC`
    • Field `identificationModule.officialTitle` changed from `A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)` to `A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)`
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-07`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2029-05-10` to `2030-11-18`
    • Field `statusModule.completionDateStruct.date` changed from `2030-03-25` to `2030-11-18`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-21` to `2026-07-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-22` to `2026-07-14`
    • Field `descriptionModule.briefSummary` changed from `The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.` to `The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.`
    • Field `descriptionModule.detailedDescription` changed from `This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with non-squamous mNSCLC whose tumors express PD-L1 (TC ≥ 1%).` to `This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1 (TC ≥ 1%).`
    • Field `designModule.enrollmentInfo.count` changed from `878` to `1160`
    • Field `outcomesModule.primaryOutcomes.[0]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.primaryOutcomes.[1]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[0]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[1]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[2]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[3]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[4]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[5]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[6]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[7]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[8]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `outcomesModule.secondaryOutcomes.[9]timeFrame` changed from `Up to approximately 5 years` to `Up to approximately 6 years`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Histologically or cytologically documented non-squamous NSCLC.
      • Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
      • Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements.
      • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
      • Provision of acceptable tumor sample, to confirm tumor PD-L1 expression TC ≥ 1%.
      • At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.
      • Adequat` to `Inclusion Criteria:
      • Histologically or cytologically documented non-squamous NSCLC.
      • Stage III B/C or IV NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
      • Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements.
      • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved and available targeted 1L therapies.
      • Provision of acceptable tumor sample, to confirm tumor PD-L1 expression TC ≥ 1%.
      • At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated`
    • Field `contactsLocationsModule.locations.[34]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[113]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[124]status` changed from `ACTIVE_NOT_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[147]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[149]status` changed from `RECRUITING` to `NOT_YET_RECRUITING`
    • Field `contactsLocationsModule.locations.[149]city` changed from `Cologne` to `Bochum`
    • Field `contactsLocationsModule.locations.[149]zip` changed from `51109` to `44791`
    • Field `contactsLocationsModule.locations.[149]geoPoint.lat` changed from `50.93333` to `51.48165`
    • Field `contactsLocationsModule.locations.[149]geoPoint.lon` changed from `6.95` to `7.21648`
    • Field `contactsLocationsModule.locations.[150]city` changed from `Esslingen am Neckar` to `Cologne`
    • Field `contactsLocationsModule.locations.[150]zip` changed from `73730` to `51109`
    • Field `contactsLocationsModule.locations.[150]geoPoint.lat` changed from `48.73961` to `50.93333`
    • Field `contactsLocationsModule.locations.[150]geoPoint.lon` changed from `9.30473` to `6.95`
    • Field `contactsLocationsModule.locations.[151]city` changed from `Frankfurt` to `Esslingen am Neckar`
    • Field `contactsLocationsModule.locations.[151]zip` changed from `60488` to `73730`
    • Field `contactsLocationsModule.locations.[151]geoPoint.lat` changed from `49.68333` to `48.73961`
    • Field `contactsLocationsModule.locations.[151]geoPoint.lon` changed from `10.53333` to `9.30473`
    • Field `contactsLocationsModule.locations.[152]city` changed from `Gauting` to `Frankfurt`
    • Field `contactsLocationsModule.locations.[152]zip` changed from `82131` to `60488`
    • Field `contactsLocationsModule.locations.[152]geoPoint.lat` changed from `48.06919` to `49.68333`
    • Field `contactsLocationsModule.locations.[152]geoPoint.lon` changed from `11.37703` to `10.53333`
    • Field `contactsLocationsModule.locations.[153]city` changed from `Giessen` to `Gauting`
    • Field `contactsLocationsModule.locations.[153]zip` changed from `35392` to `82131`
    • Field `contactsLocationsModule.locations.[153]geoPoint.lat` changed from `50.58727` to `48.06919`
    • Field `contactsLocationsModule.locations.[153]geoPoint.lon` changed from `8.67554` to `11.37703`
    • Field `contactsLocationsModule.locations.[154]city` changed from `Großhansdorf` to `Giessen`
    • Field `contactsLocationsModule.locations.[154]zip` changed from `22927` to `35392`
    • Field `contactsLocationsModule.locations.[154]geoPoint.lat` changed from `53.66528` to `50.58727`
    • Field `contactsLocationsModule.locations.[154]geoPoint.lon` changed from `10.28552` to `8.67554`
    • Field `contactsLocationsModule.locations.[155]city` changed from `Hamburg` to `Großhansdorf`
    • Field `contactsLocationsModule.locations.[155]zip` changed from `20251` to `22927`
    • Field `contactsLocationsModule.locations.[155]geoPoint.lat` changed from `53.55073` to `53.66528`
    • Field `contactsLocationsModule.locations.[155]geoPoint.lon` changed from `9.99302` to `10.28552`
    • Field `contactsLocationsModule.locations.[156]city` changed from `Hanover` to `Hamburg`
    • Field `contactsLocationsModule.locations.[156]zip` changed from `30459` to `20251`
    • Field `contactsLocationsModule.locations.[156]geoPoint.lat` changed from `52.37052` to `53.55073`
    • Field `contactsLocationsMod
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-26` to `2026-05-21`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-27` to `2026-05-22`
    • Field `contactsLocationsModule.locations.[20]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[37]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[127]geoPoint.lat` changed from `22.8836` to `30.17415`
    • Field `contactsLocationsModule.locations.[127]geoPoint.lon` changed from `107.264` to `120.97629`
    • Field `contactsLocationsModule.locations.[255]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[256]city` changed from `Taoyuan District` to `Taoyuan`
    • Field `contactsLocationsModule.locations.[256]geoPoint.lat` changed from `24.9896` to `24.99368`
    • Field `contactsLocationsModule.locations.[256]geoPoint.lon` changed from `121.3187` to `121.29696`
    • Field `contactsLocationsModule.locations.[259]geoPoint.lat` changed from `13.7775` to `13.77706`
    • Field `contactsLocationsModule.locations.[259]geoPoint.lon` changed from `100.51977` to `100.51958`
  • 2026-03-28 02:22:27 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-11` to `2026-03-26`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-12` to `2026-03-27`
    • Field `contactsLocationsModule.locations.[31]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[89]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[146]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[152]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[172]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[178]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[211]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-16 21:08:12 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-02-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-22` to `2026-02-12`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[179]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[183]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[196]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[202]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[232]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`

NCT04305054

  • 2026-05-29 03:42:24 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `COMPLETED`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-05-20` to `2026-05-18`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2026-05-20` to `2026-05-18`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-07` to `2026-05-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-08` to `2026-05-28`
    • Field `designModule.enrollmentInfo.count` changed from `315` to `335`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[26]state` changed from `Región de la Araucanía` to `Araucania`
  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-04-20` to `2026-05-20`
    • Field `statusModule.completionDateStruct.date` changed from `2026-04-20` to `2026-05-20`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-08-28` to `2026-04-07`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-29` to `2026-04-08`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[46]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[45]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04294810

  • 2026-06-24 14:19:42 (Trial Update)
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `31.00435` to `27.46194`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `-108.15213` to `-109.94134`
  • 2026-05-30 03:31:20 (Trial Update)
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `22.75904` to `31.00435`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `-98.98718` to `-108.15213`
  • 2026-05-26 02:38:41 (Trial Update)
    • Field `contactsLocationsModule.locations.[34]geoPoint.lat` changed from `22.4143` to `25.3238`
    • Field `contactsLocationsModule.locations.[34]geoPoint.lon` changed from `108.78745` to `105.583`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `31.00435` to `22.75904`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `-108.15213` to `-98.98718`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[56]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[56]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[56]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[48]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[48]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[48]geoPoint.lon` changed from `14.5195` to `14.26811`

📥 Download Full Data (CSV) 📥 Download Status Summary (CSV)

Monitoring Status

Trial ID Sponsor Update Status Conditions Phases Start End Enroll Last Updated
NCT04818619 Assiut University No Change Unknown Chronic Myeloid Leukemia N/A 2021-04 2022-12 65 2021-03-25
NCT04150965 Multiple Myeloma Research Cons… No Change Terminated Multiple Myeloma, Relapsed Ref… PHASE1 PHASE2 2020-07-10 2024-08-30 14 2025-02-12
NCT05607563 Biotheus Inc. Changed Unknown Advanced Tumor PHASE1 2022-11-21 2023-12 54 2023-02-07
NCT05394168 Shanghai Henlius Biotech No Change Unknown Advanced/Metastatic Solid Tumo… PHASE1 2022-12-09 2025-03-04 12 2024-03-28
NCT07171307 Instituto de Oftalmología Fund… No Change Not Yet Recruiting Conjunctivitis, Allergic N/A 2026-01-01 2026-09 60 2025-09-15
NCT04995523 AstraZeneca Changed Active Not Recruiting Non-Small-Cell Lung Carcinoma PHASE1 PHASE2 2021-09-14 2028-06-01 212 2026-07-13
NCT03119428 OncoMed Pharmaceuticals, Inc. No Change Terminated Locally Advanced Cancer, Metas… PHASE1 2017-05-02 2019-05-15 33 2020-08-10
NCT04500678 University of Hawaii No Change Unknown HIV/AIDS PHASE2 PHASE3 2019-02-01 2022-12-31 38 2020-08-04
NCT05483400 University Medical Center Gron… No Change Recruiting Head and Neck Neoplasms, MSI-H… PHASE2 2023-10-18 2027-09 97 2025-03-28
NCT05390528 Shanghai Henlius Biotech No Change Unknown Advanced Tumors, Lymphoma, Met… PHASE1 PHASE2 2022-06-20 2024-12-30 30 2023-08-07
NCT06250036 Royal Marsden NHS Foundation T… No Change Recruiting Locally Advanced Gastric Adeno… PHASE2 2025-02-20 2031-09-01 50 2025-08-19
NCT05653284 Akeso No Change Completed Advanced Malignant Tumors PHASE1 2023-02-09 2024-05-30 19 2024-08-11
NCT05102214 Shanghai Henlius Biotech No Change Unknown Locally Advanced or Metastatic… PHASE1 PHASE2 2022-05-03 2024-02 150 2023-08-07
NCT05023109 Shanghai Zhongshan Hospital No Change Unknown Biliary Tract Carcinoma PHASE2 2021-02-01 2024-12-01 45 2023-08-12
NCT05130177 Diwakar Davar No Change Active Not Recruiting Melanoma PHASE2 2022-03-16 2030-01-31 8 2026-03-25
NCT04047862 BeiGene No Change Completed Locally Advanced and Metastati… PHASE1 2019-08-15 2024-08-07 446 2025-08-04
NCT05537051 Biotheus Inc. Changed Unknown Advanced Solid Tumours PHASE1 2023-10-30 2025-12-31 30 2023-02-07
NCT05019677 Fudan University No Change Withdrawn Intrahepatic Cholangiocarcinom… PHASE2 2021-09-01 2024-12-01 0 2022-03-22
NCT05061628 Shanghai Junshi Bioscience Co…. Changed Completed Advanced Tumors PHASE1 2021-04-21 2023-04-23 47 2026-07-08
NCT04656535 Yale University No Change Active Not Recruiting Glioblastoma EARLY_PHASE1 2021-04-21 2026-12-31 46 2026-04-15
NCT06773507 Sichuan Luzhou Buchang Biophar… No Change Recruiting Advanced Esophageal Cancers, A… PHASE1 2025-05-12 2027-06 80 2025-07-07
NCT06349980 Shanghai Henlius Biotech No Change Recruiting Carcinoma, Hepatocellular PHASE2 2024-08-05 2027-02-10 117 2024-12-15
NCT05706207 Huabo Biopharm Co., Ltd. No Change Unknown Advanced Solid Tumor PHASE1 2021-12-21 2023-09-30 36 2023-01-20
NCT05060432 iTeos Belgium SA Changed Unknown Advanced Cancer, Lung Cancer, … PHASE1 PHASE2 2021-09-06 2025-07 153 2024-06-19
NCT06713798 Gustave Roussy, Cancer Campus,… No Change Withdrawn Metastatic Cancer Lung, Advanc… PHASE2 2025-01-30 2025-09-15 0 2026-03-19
NCT05394337 M.D. Anderson Cancer Center No Change Recruiting Metastatic Malignancy PHASE1 PHASE2 2023-02-23 2028-12-31 10 2026-04-30
NCT05253105 Shanghai Junshi Bioscience Co…. No Change Withdrawn Previously Treated, Advanced, … PHASE1 2022-03-15 2027-01 0 2022-05-24
NCT04270942 Provention Bio, a Sanofi Compa… No Change Completed Diabetes Mellitus, Type 1 PHASE2 2020-02-26 2024-01-22 6 2025-01-20
NCT05294952 Assiut University No Change Unknown Pre-Eclampsia PHASE4 2025-01-01 2025-11-04 82 2024-02-01
NCT06754501 M.D. Anderson Cancer Center No Change Active Not Recruiting Cancer PHASE2 2025-04-11 2029-07-01 4 2026-02-16
NCT05757492 Coherus Oncology, Inc. No Change Terminated Advanced Solid Tumor, Non-Smal… PHASE1 2023-04-26 2024-07-31 22 2025-04-30
NCT04952597 BeiGene No Change Completed Limited Stage Small Cell Lung … PHASE2 2021-07-15 2023-07-26 126 2024-10-23
NCT05805501 Hoffmann-La Roche No Change Active Not Recruiting Renal Cell Carcinoma PHASE2 2023-04-21 2026-10-31 199 2026-05-11
NCT03447678 Fondazione IRCCS Istituto Nazi… No Change Unknown Non Small Cell Lung Cancer (NS… PHASE2 2018-05-23 2022-05-31 65 2021-06-08
NCT04672369 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Lung Cancer PHASE1 2021-06-06 2023-06-01 42 2023-06-18
NCT04672356 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Lung Cancer PHASE1 2021-01-25 2023-06-01 19 2023-06-18
NCT05009069 Hoffmann-La Roche Changed Active Not Recruiting Rectal Neoplasms, Rectal Cance… PHASE2 2022-03-18 2026-11-10 58 2026-07-27
NCT04353830 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Malignancies PHASE1 2020-05-22 2022-05-11 34 2023-02-28
NCT07337447 Hospices Civils de Lyon No Change Not Yet Recruiting Carcinoma, Neuroendocrine PHASE2 2026-04 2030-04 122 2026-01-07
NCT04354246 Compugen Ltd No Change Completed Advanced Cancer, Ovarian Cance… PHASE1 2020-03-31 2026-04-01 94 2026-05-11
NCT04933227 Hoffmann-La Roche No Change Terminated Stomach Neoplasms, Gastric Can… PHASE2 2021-08-06 2023-11-17 29 2024-11-11
NCT05414032 University Health Network, Tor… No Change Recruiting Locoregionally Advanced Head a… PHASE2 2023-07-12 2028-07 102 2026-02-23
NCT06003621 Omico No Change Recruiting Solid Tumor, Adult PHASE2 2023-12-15 2028-11-01 96 2024-11-13
NCT05568095 Arcus Biosciences, Inc. Changed Active Not Recruiting Advanced Upper Gastrointestina… PHASE3 2022-11-21 2026-08 1,040 2026-07-20
NCT06777628 IRCCS Azienda Ospedaliero-Univ… No Change Recruiting Liver Cancer, Adult N/A 2024-09-15 2028-10-15 100 2025-01-14
NCT06773481 Sichuan Luzhou Buchang Biophar… No Change Recruiting Glioma, Glioma Tumor Recurrenc… PHASE1 2025-04-07 2026-12 40 2025-07-07
NCT03708224 Alain Algazi No Change Recruiting Cancer, Carcinoma, Squamous Ce… PHASE2 2019-03-08 2028-06-30 55 2025-01-24
NCT03652402 Assistance Publique - Hôpitaux… No Change Completed Kidney Transplant Rejection, K… N/A 2018-11-27 2021-10-28 558 2024-06-04
NCT03486119 Yonsei University No Change Completed Non -Small Cell Lung Cancer N/A 2018-02-05 2020-07-07 60 2020-10-14
NCT05120375 Bio-Thera Solutions No Change Terminated Solid Tumor PHASE1 2022-02-17 2023-04-07 5 2023-10-08
NCT05327530 EMD Serono Research & Developm… No Change Active Not Recruiting Locally Advanced or Metastatic… PHASE2 2022-08-17 2026-06-25 256 2026-04-23
NCT04570839 Compugen Ltd No Change Completed Endometrial Neoplasms, Ovarian… PHASE1 PHASE2 2020-08-31 2024-05-15 48 2024-07-17
NCT05520294 University of Colorado, Denver No Change Unknown Melanoma N/A 2022-09-01 2024-08-31 90 2024-04-15
NCT05417321 Shanghai Huaota Biopharmaceuti… No Change Recruiting Advanced Solid Tumor, NSCLC PHASE1 PHASE2 2022-08-25 2025-08-01 80 2025-01-02
NCT06328036 National Cancer Institute (NCI… No Change Withdrawn Recurrent Glioblastoma, IDH-Wi… PHASE2 2025-04-30 2025-07-01 0 2024-12-27
NCT04465643 Sidney Kimmel Comprehensive Ca… Changed Completed Nerve Sheath Tumors PHASE1 2021-06-08 2025-07-30 13 2026-07-09
NCT04262856 Arcus Biosciences, Inc. No Change Completed Non Small Cell Lung Cancer, No… PHASE2 2020-05-28 2025-07-09 151 2026-06-11
NCT04736173 Arcus Biosciences, Inc. Changed Active Not Recruiting Non Small Cell Lung Cancer, No… PHASE2 2021-02-08 2027-05 169 2026-07-28
NCT05126537 Southeast University, China No Change Unknown 28 Day Mortality N/A 2022-01-01 2022-12-31 100 2022-11-25
NCT05289492 iTeos Therapeutics No Change Terminated Multiple Myeloma PHASE1 2022-05-01 2023-11-29 16 2024-10-23
NCT07115043 AstraZeneca Changed Recruiting Melanoma, Non-small Cell Lung … PHASE1 PHASE2 2025-07-29 2029-10-02 60 2026-07-06
NCT05743504 National Taiwan University Hos… No Change Unknown Locally Advanced Esophageal Sq… PHASE1 PHASE2 2023-09-18 2025-11-30 32 2024-01-31
NCT05073484 Bio-Thera Solutions No Change Terminated Advanced Solid Tumor PHASE1 2021-10-29 2023-03-30 13 2023-10-09
NCT07376512 Centre Georges Francois Lecler… No Change Not Yet Recruiting Non-Small Cell Lung Cancer, Me… N/A 2026-03-01 2030-03-01 378 2026-01-22
NCT05904886 Hoffmann-La Roche No Change Active Not Recruiting Hepatocellular Carcinoma PHASE3 2023-09-14 2026-09-01 687 2025-12-30
NCT03739710 GlaxoSmithKline No Change Completed Neoplasms PHASE2 2019-01-24 2024-05-02 175 2025-06-13
NCT04791839 Washington University School o… No Change Active Not Recruiting Non Small Cell Lung Cancer, No… PHASE2 2021-08-04 2030-12-31 30 2026-06-04
NCT05020912 Case Comprehensive Cancer Cent… No Change Active Not Recruiting Basal Cell Carcinoma PHASE2 2021-12-13 2027-12 18 2026-05-28
NCT06334406 Centre Hospitalier Universitai… No Change Unknown Bladder Cancer N/A 2024-04-02 2026-04-02 33 2024-03-19
NCT07343310 Kine Sciences Co., Ltd. No Change Completed CIDP - Chronic Inflammatory De… PHASE1 2024-08-27 2025-04-14 9 2026-01-15
NCT03342417 ExcellaBio LLC No Change Terminated Breast Cancer Female, Ovarian … PHASE2 2018-02-14 2019-05-29 5 2021-11-05
NCT04682665 University of Leeds No Change Completed Colon Cancer Liver Metastasis N/A 2021-09-16 2024-07-31 81 2024-12-03
NCT05123482 AstraZeneca Changed Recruiting Breast Cancer, Biliary Tract C… PHASE1 PHASE2 2021-10-18 2027-09-29 460 2026-07-15
NCT07161414 AstraZeneca Changed Recruiting Advanced Solid Tumors PHASE1 2025-11-25 2029-07-24 40 2026-07-08
NCT07015164 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting HIV N/A 2025-06-10 2026-09-11 80 2025-06-03
NCT05702229 AstraZeneca No Change Recruiting Gastric Cancer PHASE2 2023-01-16 2029-05-31 163 2026-05-13
NCT07213882 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting Cutaneous T Cell Lymphoma (CTC… EARLY_PHASE1 2026-01-01 2028-08-01 30 2025-10-02
NCT03628677 Arcus Biosciences, Inc. No Change Completed Solid Tumor, Unspecified, Adul… PHASE1 2018-09-12 2025-01-23 75 2025-02-03
NCT06897436 Medical University of Lublin No Change Not Yet Recruiting Endometriosis N/A 2025-05-01 2029-12-31 60 2025-03-24
NCT05633927 Hospitales Universitarios Virg… No Change Completed SARS-CoV-2 RNA Vaccines, HIV I… N/A 2021-04-01 2022-12-01 48 2024-10-09
NCT04836507 Curocell Inc. Changed Recruiting Relapsed Large B-cell Lymphoma… PHASE1 PHASE2 2021-03-02 2030-09-26 91 2026-06-29
NCT05775159 AstraZeneca Changed Active Not Recruiting Hepatocellular Carcinoma, Bili… PHASE2 2023-04-24 2027-10-28 294 2026-07-01
NCT06338657 University of Southern Califor… No Change Terminated Head and Neck Squamous Cell Ca… PHASE1 2024-04-01 2025-09-09 1 2025-09-09
NCT06860815 City of Hope Medical Center No Change Recruiting Anatomic Stage IV Breast Cance… PHASE2 2026-01-30 2027-01-30 11 2026-05-18
NCT04624828 Istituto Clinico Humanitas No Change Active Not Recruiting Oligorecurrent and Oligoprogre… NA 2020-10-19 2026-07 40 2025-04-22
NCT05574335 National Institute of Allergy … Changed Terminated Type 1 Diabetes Mellitus PHASE1 PHASE2 2023-05-18 2025-10-20 8 2026-06-30
NCT06302556 Fondazione IRCCS Ca' Granda, O… No Change Unknown Lung Transplant Rejection N/A 2024-04 2026-02 280 2024-03-06
NCT04761198 Mereo BioPharma No Change Completed Solid Tumor, Adult, Advanced S… PHASE1 PHASE2 2021-03-23 2023-10-30 76 2025-03-07
NCT04693234 BeiGene No Change Completed Cervical Cancer PHASE2 2021-02-15 2023-08-31 178 2025-04-09
NCT03563716 Genentech, Inc. No Change Completed Non-small Cell Lung Cancer PHASE2 2018-08-10 2025-11-14 135 2026-04-13
NCT07324642 Kine Sciences Co., Ltd. No Change Completed Healthy Volunteers PHASE1 2025-05-26 2025-08-25 24 2025-12-24
NCT05809895 Novartis Pharmaceuticals No Change Withdrawn Triple Negative Breast Cancer PHASE2 2023-09-15 2029-07-18 0 2023-07-21
NCT04732494 BeiGene No Change Completed Esophageal Squamous Cell Carci… PHASE2 2021-03-31 2023-12-26 125 2024-12-23
NCT05645692 Hoffmann-La Roche Changed Active Not Recruiting Urothelial Cancer PHASE2 2023-04-13 2026-12-31 204 2026-07-27
NCT04457778 EMD Serono Research & Developm… No Change Completed Metastatic Solid Tumors PHASE1 2020-07-10 2023-06-23 58 2026-04-13
NCT03772899 London Health Sciences Centre … No Change Active Not Recruiting Melanoma PHASE1 2019-03-27 2026-08 20 2025-03-26
NCT04374877 Coherus Oncology, Inc. Changed Completed Advanced Solid Tumor, Clear Ce… PHASE1 2020-04-22 2025-06-05 145 2026-07-14
NCT06346197 Centre Leon Berard Changed Recruiting Gastric Cancer, MSI-H, Metasta… PHASE3 2025-12-08 2028-05-15 132 2026-06-23
NCT05780073 Fundació Institut Germans Tria… No Change Completed HIV Infection Primary PHASE2 2023-10-16 2025-04-01 60 2025-09-16
NCT03667716 Compugen Ltd No Change Completed Advanced Cancer, Ovarian Cance… PHASE1 2018-09-06 2024-01-30 121 2025-01-15
NCT06784947 University of Colorado, Denver No Change Active Not Recruiting Microsatellite Stable (MSS) Co… PHASE2 2025-03-25 2028-05 13 2025-10-01
NCT05014815 BeiGene No Change Completed Locally Advanced, Unresectable… PHASE2 2021-11-16 2024-09-04 272 2025-08-28
NCT07307053 Cancer Institute and Hospital,… No Change Not Yet Recruiting Rare Malignant Neoplasm, Advan… PHASE1 PHASE2 2026-01-01 2031-01-31 600 2025-12-13
NCT04746924 BeiGene Changed Terminated Non-small Cell Lung Cancer, NS… PHASE3 2021-05-24 2026-03-18 669 2026-04-20
NCT07098338 AstraZeneca Changed Recruiting Non-Small Cell Lung Cancer PHASE2 2025-08-07 2029-04-06 278 2026-06-30
NCT06532539 Shandong Cancer Hospital and I… No Change Recruiting Endometrial Neoplasms, Neoplas… PHASE2 2024-06-13 2026-09 30 2026-04-21
NCT06864598 Peking University People's Hos… No Change Enrolling By Invitation Graft-versus-host Disease (GVH… N/A 2025-01-09 2026-10-31 100 2025-03-04
NCT03661047 Massachusetts General Hospital No Change Withdrawn Colon Cancer PHASE2 2019-11-30 2021-11-30 0 2021-11-10
NCT04866017 BeiGene No Change Terminated Non Small Cell Lung Cancer PHASE3 2021-06-17 2023-10-17 63 2024-10-09
NCT05127824 Jodi Maranchie Changed Recruiting Carcinoma, Renal Cell PHASE2 2023-07-06 2027-12 42 2026-07-03
NCT04303169 Merck Sharp & Dohme LLC No Change Completed Melanoma PHASE1 PHASE2 2020-06-26 2025-09-24 146 2025-10-23
NCT05329766 Arcus Biosciences, Inc. Changed Active Not Recruiting Gastrointestinal Tract Maligna… PHASE2 2022-06-10 2027-06 332 2026-07-28
NCT04323202 Case Comprehensive Cancer Cent… No Change Completed Basal Cell Carcinoma of the He… PHASE1 2020-08-04 2025-06-25 13 2025-10-23
NCT07221253 AstraZeneca Changed Recruiting Biliary Tract Cancer PHASE3 2025-12-04 2029-07-31 1,100 2026-07-17
NCT05676931 Gilead Sciences No Change Active Not Recruiting Advanced Non-Small Cell Lung C… PHASE2 2023-02-21 2027-12 400 2026-05-28
NCT06790706 Hospices Civils de Lyon Changed Active Not Recruiting Peritoneal Mesothelioma, Gesta… PHASE2 2025-10-01 2031-06 27 2026-06-22
NCT04543617 Hoffmann-La Roche Changed Active Not Recruiting Esophageal Squamous Cell Carci… PHASE3 2020-09-28 2027-03-31 760 2026-07-22
NCT04305041 Merck Sharp & Dohme LLC No Change Completed Melanoma PHASE1 PHASE2 2020-06-26 2025-08-25 100 2025-08-28
NCT06996782 AstraZeneca Changed Recruiting Advanced or Metastatic Non-sma… PHASE1 PHASE2 2025-11-24 2029-02-23 152 2026-07-20
NCT05665595 Merck Sharp & Dohme LLC No Change Completed Melanoma PHASE3 2023-01-19 2025-09-26 1,594 2025-10-03
NCT06868277 AstraZeneca No Change Recruiting Carcinoma, Non-Small Cell Lung PHASE3 2025-04-10 2030-12-02 830 2026-05-13
NCT06692738 AstraZeneca Changed Recruiting Non-small Cell Lung Cancer PHASE3 2024-11-18 2030-07-01 1,160 2026-07-13
NCT04774484 Francesc Marti No Change Withdrawn End Stage Renal Disease NA 2023-01 2026-06-30 0 2023-02-10
NCT04256421 Hoffmann-La Roche No Change Completed Small Cell Lung Cancer PHASE3 2020-02-04 2025-07-31 490 2026-03-13
NCT06989112 AstraZeneca No Change Recruiting Endometrial Cancer PHASE3 2025-03-27 2031-02-19 600 2026-06-19
NCT05816460 University College Dublin No Change Unknown Insomnia, Cancer NA 2023-05-22 2024-06-10 308 2023-05-19
NCT06627647 AstraZeneca Changed Recruiting Non-squamous Non-small Cell Lu… PHASE3 2024-11-27 2030-11-18 1,160 2026-07-13
NCT04305054 Merck Sharp & Dohme LLC No Change Completed Melanoma PHASE1 PHASE2 2020-07-01 2026-05-18 335 2026-05-27
NCT04294810 Hoffmann-La Roche No Change Completed Non-Small Cell Lung Cancer PHASE3 2020-03-04 2025-12-30 620 2026-01-29
NCT03198546 Second Affiliated Hospital of … No Change Recruiting Hepatocellular Carcinoma, Immu… PHASE1 2017-07-01 2036-08-01 30 2024-06-22
NCT03198052 Second Affiliated Hospital of … No Change Recruiting Lung Cancer, Cancer, Immunothe… PHASE1 2017-07-01 2036-08-01 30 2024-06-22
NCT04585815 Pfizer No Change Terminated Carcinoma, Non-Small-Cell Lung PHASE1 PHASE2 2020-11-10 2024-10-29 34 2025-12-18
NCT02443155 Novo Nordisk A/S No Change Completed Diabetes, Diabetes Mellitus, T… PHASE2 2015-11-10 2019-02-27 308 2021-03-10
NCT06097962 Base Therapeutics (Shanghai) C… No Change Recruiting NSCLC EARLY_PHASE1 2023-07-01 2026-07-01 12 2026-05-18
NCT07561437 Base Therapeutics (Shanghai) C… No Change Recruiting Advanced Solid Tumors EARLY_PHASE1 2026-03-09 2028-10 18 2026-04-28
NCT07647055 The First Affiliated Hospital … No Change Not Yet Recruiting Multiple Pulmonary Nodules N/A 2026-07 2028-12 200 2026-06-09
NCT07647484 The First Affiliated Hospital … No Change Not Yet Recruiting Multiple Pulmonary Nodules N/A 2026-07 2028-12 200 2026-06-12
NCT07656077 ANRS, Emerging Infectious Dise… No Change Not Yet Recruiting HIV-1 Infection, HIV Reservoir… NA 2026-08-01 2030-07-31 30 2026-06-14
NCT07657585 Cancer Institute and Hospital,… No Change Not Yet Recruiting Advanced Malignant Solid Tumor… PHASE1 2026-07-01 2028-05-31 91 2026-06-14
NCT07657416 Base Therapeutics (Shanghai) C… No Change Not Yet Recruiting Hepatocellular Carcinoma (HCC)… EARLY_PHASE1 2026-06 2028-07 18 2026-06-15
NCT07679841 Centre Leon Berard No Change Not Yet Recruiting Vulvar Squamous Cell Carcinoma PHASE1 PHASE2 2026-09 2029-09 50 2026-06-25
NCT07723638 Fondazione Don Carlo Gnocchi E… No Change Not Yet Recruiting Chronic Obstructive Pulmonary … NA 2026-09-01 2027-11-13 200 2026-07-21
NCT07720284 AstraZeneca No Change Recruiting High-risk Muscle Invasive Urot… PHASE3 2026-07-16 2032-11-23 915 2026-07-17
NCT07674498 Jules Bordet Institute No Change Recruiting Myeloma Multiple NA 2026-06-03 2027-09 31 2026-06-24
NCT07667842 D3 Bio (Wuxi) Co., Ltd No Change Not Yet Recruiting Advanced Solid Tumor PHASE1 2026-07-18 2028-02-12 24 2026-06-21
NCT07707245 Fondazione Don Carlo Gnocchi E… No Change Recruiting COPD, Idiopathic Pulmonary Fib… NA 2026-04-22 2028-10-30 120 2026-07-15